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Abstract 
Objectives: To determine knowledge, practice patterns and attitudes of gastroenterologists 
and surgeons in NL regarding familial and hereditary colorectal cancer screening. 
Methods: A self-administered mail-out survey was used to collect information on 
specialist understanding of best practice colo rectal cancer screening guidelines. 
Results: Eighty- four percent of eligible specialists responded. The majority of specialists 
begin screening at the appropriate age and preferred screening with colonoscopy. 
Interdisciplinary health team involvement varied. More than half of respondents are 
seeing patients with F AP and HNPCC gene mutations for colonoscopy within 3 months. 
Almost all respondents agreed there is a need for a province wide colorectal cancer 
registry. 
Conclusions: Overwhelming preference for the colonoscopy is potentially contributing to 
extended wait times. Inconsistencies in practices are evident. Examining other models of 
colorectal cancer screening would help to provide clarity around interdisciplinary health 
team roles and guidance for moving towards a more organized screening approach. 
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Chapter One -Introduction 
1.1 Problem Statement 
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in 
Canada. It is also the second leading cause of death in the country (Health Canada, 2007). 
An estimated 22,000 Canadians are diagnosed with CRC each year and 9,100 die from it 
(Canadian Cancer Society {CCS}, 2009a). Currently Newfoundland and Labrador (NL) 
has the highest incidence rate of CRC among men (87 /1 00,000) and second highest 
incidence rate among women (52/1 00,000) (CCS, 2009a). Based on the 2009 NL cancer 
statistics estimates, a total of 280 men and 200 women will be diagnosed with CRC and 
130 men and 100 women will die from it this year (CCS, 2009a). 
Fortunately, with regular screening, CRC is one of the most preventable forms of 
cancer. Screening reduces CRC incidence by identifying (and removing) premalignant 
polyps before cancerous tumors develop. Screening also reduces CRC related mortality 
through early detection and treatment. Since 2002, Health Canada has been 
recommending annual or biennial CRC screening for all adults over the age of 50. 
Meanwhile, advancement in genetics research has enabled certain individuals to seek 
screening earlier and more frequently. This has been particularly valuable for residents of 
NL where researchers believe genetics or at least familial factors are responsible for the 
excess CRC cancer burden in this province (Green, Green, Buehler, Robb, Daftary, 
Gallinger, et al., 2007). 
Despite higher incidence and mortality rates of CRC in NL, screening rates in NL 
are among the lowest of all Canadian provinces. Based on data from the Canadian 
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Community Health Survey (CCHS) Cycle 2.1, the proportion of people who reported up-
to-date CRC screening among the provinces assessed was lowest in NL at 12.6%. As few 
as 4% of women in NL reported having a fecal occult blood test (FOBT) within the last 
two years from when the survey was conducted (Zarychanski, Chen, Bernstein & Hebert, 
2007). Evidence suggests that encounters with the health care system can have a strong 
influence on how patients perceive the burden of screening and can either facilitate or 
impede adherence to recommended screening protocols (Geary, Thomas, MacKay, 
Dorkins, Barwell & Hodgson, 2007). Based on findings from a NL study that involved 
interviews with hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers, 
issues around extended wait times for a colonoscopy, lack of continuity of care, 
difficulties scheduling screening appointments and inconsistencies in screening 
recommendations and practices among health professionals were identified as barriers to 
routine screening (J. Stokes, Research Coordinator, personal communication, October 21, 
2008)1• 
Gastroenterologists and general surgeons play a critical role in CRC screening in 
NL. These specialists are the only health professionals who perform colonoscopy, the 
endoscopy procedure most recommended for screening the high risk familial and 
hereditary CRC populations (Leddin, Hunt, Champion, Cockeram, Flook, Gould, et al., 
2004; Levin, Lieberman, McFarland, Smith, Brooks, Andrews, et al. , 2008). In many 
cases, specialists independently prioritize care for their patients and may or may not 
assume responsibility for scheduling follow-up screening (Dr. W. Pollett, Chair of 
1 Jackie Stokes has been involved with coordinating a 2007/08 research project in NL that involved 
qualitative interviews with HNPCC mutations carriers and their experiences pursuing CRC screening. 
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Surgery for the Faculty of Medicine at Memorial University, personal communication, 
October 6, 2008). Each specialist also determines which screening test to use, the age at 
which to begin screening and the frequency of repeat screening. This approach 
contributes to the confusion among health professionals and health administrators about 
the role the specialists play in the on-going surveillance and management of the familial 
and hereditary CRC populations. 
1.2 Research Questions and Objectives 
The purpose of this cross-sectional descriptive study is to determine whether 
gastroenterologists and general surgeons are knowledgeable about familial and hereditary 
CRC and associated risk factors and whether they follow best practice screening 
guidelines. Using a self-administered mail-out survey, the research objectives are: 
1. To describe the specialists' characteristics including years since graduation, 
number of years practicing in NL, professional body certification, community size 
and number of colonoscopies performed annually. 
2. To describe the specialists' knowledge of best practice guidelines and practice 
patterns for screening individuals with family history of CRC, a family history of 
adenomatous polyps (AP), HNPCC and familial adenomatous polyposis (F AP). 
3. To describe the specialists' attitudes about current CRC screening services in NL 
including their attitudes about a provincially organized screening approach. 
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1.3 Rationale 
CRC presents a significant burden on both the individual and society. For the 
individual, the burden is reflected in the potential years of life lost, the cost of treatment, 
the degree of disability, pain, and discomfort, and the impact on the family. For society, 
the burden may be described by mortality, morbidity and the costs of treatments (Health 
Canada, 2002). A study by O'Brien, Brown, and Kephart (2001) found hospital costs for 
a cohort of CRC patients (n = 593) in Nova Scotia over a three year period after diagnosis 
amounted to $9.8 million. Costs were significantly lower for patients with localized 
cancer, higher in the six months around the time of diagnosis and throughout the six 
months before death, and highest in patients who were older and had significant co-
morbidities. Costs incurred in the three years after diagnosis were estimated to be less if 
the cancer was diagnosed early. This suggests that costs of CRC care may be reduced by 
screening for the disease and diagnosing it at an earlier stage. 
Health Canada acknowledges that the benefits of CRC screening are most likely to be 
realized if offered through an organized screening program (McLeod, 2001 ). Included in 
this approach are evidenced-based screening and follow-up guidelines, recruitment and 
retention strategies to maximize participation, and quality assurance and information 
systems to support optimal program operation (CCS, 2009b ). Currently in NL, there is no 
organized CRC screening program or CRC registry for either the general (average risk) or 
high risk familial and hereditary CRC populations. Individuals seeking screening are 
often left to navigate through the health care system alone and on an ad hoc basis (Dr. J. 
Green, Medical Geneticist at Memorial University, personal communication, August 18, 
2008). This is concerning, particularly for the familial and hereditary CRC populations, 
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because it is speculated that without adequate resources, individuals may have 
reservations about participating in genetic testing because of the challenges involved in 
managing screening protocols (J. Stokes, Research Coordinator, personal communication, 
October 21 , 2008). 
Screening of high risk familial and hereditary CRC populations begins earlier and 
occurs more frequently than does screening of the general (average risk) population. 
Often screening requires trained endoscopists to perform colonoscopy (Leddin et al. , 
2004). To date, very few studies have examined endoscopy specialists' knowledge and 
practice patterns around familial and hereditary CRC. Findings from this study identify if 
NL specialists' are knowledgeable about familial and hereditary CRC and related risk 
factors, their CRC screening practices and whether they are providing initial and follow-
up CRC screening within a timely fashion. Information about interdisciplinary health 
professional involvement and overall level of satisfaction among the specialists about 
current CRC screening services in the province is also collected. 
Combining findings from this study with the information about HNPCC patient 
experiences pursuing CRC screening in NL (J. Stokes, Research Coordinator, personal 
communication, October 21, 2008., 2008) will allow for a comprehensive understanding 
of CRC screening practices and services in the province. This knowledge will help to 
guide a provincial strategic plan to better manage CRC screening, particularly for high 
risk familial and hereditary CRC populations. 
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Chapter Two -Background and Literature Review 
2.1 Colorectal Cancer 
CRC is a malignant tumour ofthe digestive tract. The majority ofCRC cases start 
in the cells that line the walls inside the colon or the rectum (CCS, 2009c). The colon and 
rectum make up the large intestine (large bowel) which is located in the last part of the 
digestive system (see Figure 1 ). After a relatively long period of localization in the wall 
of the colon or rectum, the tumour metastasizes to regional lymph nodes and distant 
organs (CCS, 2009c) 
ascending <olon 
~-+-'~ rectum 
Y---+-HI-e anus 
The Large Intestine 
di!Scendlng 
colon 
Figure 1. Human Digestive System. Note: From the Canadian Cancer Society (2009c). 
Used with permission of the organization. 
Prognosis and survival rates for CRC are related to stage at diagnosis. The overall 
five year survival rate for CRC is approximately 50% but if caught early, the rate 
increases to almost 90% for localized CRC. Conversely, the five-year survival rate falls 
below 50% once the disease has spread (Health Canada, 2002). 
6 
2.1.1 Natural History 
Colorectal tumoms arise through complex interactions between genetic and non-
genetic (environmental) influences (Alberta Cancer Board, 2008). The tumors present as 
neoplasms (abnormal growth of tissue) ranging from benign growth to invasive cancer 
and can be classified into three groups: 
• non-neoplastic polyps, 
• neoplastic polyps (AP, adenomas), and 
• cancers (CCS, 2009c) 
In general, CRC has a long pre-symptomatic stage. It can take up to ten years or 
more for a polyp to become malignant (Ahmed, Saleem & Kadla, 2005). It is estimated 
that approximately one-half to two-thirds of all polyps are adenomatous and it is 
generally accepted that the majority of cancers of the colon and rectum develop from 
them (Health Canada, 2002). Most AP occur sporadically (60-85%) with the remainder 
due to family histories of CRC or AP including genetic mutations (McLeod, 200 I). 
2.1.2 Risk Factors 
Risk factors for CRC can be classified as modifiable or non-modifiable. A 
modifiable risk factor is defined as something that can be changed by intervention, 
thereby reducing the probability of occurrence of disease (Last, 2001). Personal behavior 
and lifestyle are considered modifiable. Non-modifiable risk factors include inborn or 
inherited characteristics which, on the basis of epidemiological evidence are known to be 
associated with health related condition(s) (Last, 2001). Some of these non-modifiable 
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risk factors include age, family history, hereditary syndromes and personal medical 
history. Examples of these risk factors are discussed below with particular emphasis on 
the non-modifiable factors. 
2.1.2.1 Age 
It is estimated that 70% of CRC cases are diagnosed in those older than age 65 
and 40% of cases are diagnosed in those over 75 years of age (National Cancer Institute, 
2001; Edwards, Howe, Ries, Thun, Rosenberg, Yancik, et al. 2002). While the incidence 
and mortality rates associated with CRC in Canada are falling with improved screening, it 
is projected that the absolute number of new cases and deaths will probably continue to 
rise due to the aging of the "baby-boom" generation (Health Canada, 2002). 
2.1.2.2 Family history of CRC or AP 
Individuals with a family history of CRC or AP are at a significantly increased 
risk of developing CRC. Actual level of risk depends largely on the closeness of the 
relationship, the age at which a family member was diagnosed with CRC or AP, and the 
number of affected relatives (Eisen & Weinberg, 2005). In a meta-analysis of 27 case-
control and cohort studies by Johns and Houlston (200 1) to determine familial risk of 
CRC, the relative risk ofCRC was 1.99 with a first-degree relative with AP, 2.25 with a 
first-degree relative with CRC, 3.87 with a first degree relative with CRC before age 45 
years and 4.25 with more than one first-degree relative with CRC. 
2.1.2.3. Family history ofHNPCC and FAP 
Hereditary syndromes are estimated to account for approximately five to ten 
percent of all cases of CRC (Lynch & de le Chapelle, 2003). HNPCC and F AP are the 
two most common CRC hereditary syndromes. Both present in an autosomal dominant 
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manner and specific gene mutations associated with both disorders have been identified. 
F AP is associated with mutations in the APC (adenomatous polyposis coli) gene and 
presents with hundreds or even thousands of polyps throughout the large intestine. These 
benign polyps generally develop between ten and 20 years of age and if left untreated, 
affected individuals have an almost 100% risk for developing CRC (Merg, Lynch, Lynch 
& Howe, 2005). A variant ofF AP, known as attenuated F AP or attenuated adenomatous 
polyposis coli, may involve between 20-100 AP proximally distributed in the colon. The 
onset of CRC is approximately ten years later for attenuated FAP than for classical F AP 
(Leddin et al., 2004). 
HNPCC is associated with mutations in several mismatch repair genes including 
MSH2, MLH1 , MSH6, and PMS2. Ninety percent of cases are caused by mutations in 
either MLH1 or MSH2 (Lynch & dele Chapelle, 2003). HNPCC shows incomplete 
penetrance meaning that not all mutation carriers will develop a cancer (Stuckless, 
Parfrey, Woods, Cox, Fitzgerald, Green, et al., 2007). The lifetime risk of developing 
CRC with HNPCC is up to 80% with a median age of diagnosis of 45 years (Bametson, 
Tenesa, Farringonton, Nicholl, Cetnarskyj, Porteous, et al. , 2006). Unlike FAP, HNPCC 
involves only a few polyps, however, these polyps may progress more rapidly from 
adenoma to cancer (Lynch & Lynch, 1998). Mutation carriers also have an increased risk 
for several extra colonic neoplasms including endometrial, small-bowel, gastric, renal 
pelvis, ureter, and ovarian cancers (Lynch & Smyrk, 1999). 
To help promote consistency in recognizing those at high risk for HNPCC, a set of 
guidelines, known as the Amsterdam Criteria, was developed in 1991 by the International 
Collaborative Group on HNPCC. The guidelines are as follows: 
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1) At least three members ofthe family have CRC (FAP excluded), one of whom is a 
first-degree relative of the other two; 
2) Two or more generations are affected; and 
3) At least one relative was diagnosed before age 50 years (Vasen, Mecklin, Khan & 
Lynch, 1991). 
These guidelines were later revised to be less restrictive because patients were 
discovered with identified HNPCC mutations but who did not meet these criteria. The 
new guidelines are known as Amsterdam II (Vasen, Watson, Mecklin & Lynch, 1999) 
and they also take into account the extra colonic cancers associated with HNPCC. Details 
of the guidelines can be found in Appendix A. 
2.1.2.4 Other diseases/conditions 
A personal medical history of a chronic inflammatory bowel disease such as 
ulcerative colitis and Crohn' s disease is another risk factor for CRC (Bernstein, 
Blanchard, Kliewer & Wajda, 2001). People who have previously had CRC are also more 
likely to develop a new cancer in other areas of the colon and rectum, even if the CRC 
was completely removed. This is especially true if the first CRC developed before 60 
years of age (Renehan, Egger, Saunders & O'Dwyer, 2002). 
2.1.2.5 Modifiable risk factors 
It has been estimated by the American Institute for Cancer Research and the 
World Cancer Research Fund that 30 to 40 percent of all cancers can be prevented by 
appropriate diets, physical activity, and maintenance of appropriate body weight (World 
Cancer Research Fund I American Institute for Cancer Research, 2009). In a recent US 
prospective study population of more than 900,000 adults, overweight and obesity were 
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estimated to account for 14 percent of all cancer deaths in men and 20 percent of those in 
women during a 16-year follow up (Calle, Rodriguez, Walker-Thurmond & Thun, 2003). 
One of the most important messages around nutrition and cancer prevention is the 
importance of a diet rich in fruits and vegetables. A review of the relationship between 
vegetable and fruit consumption and cancer in 206 human epidemiologic studies and 22 
animal studies found evidence to suggest an increased intake of vegetables and fruit 
helped to prevent cancers of the stomach, esophagus, lung, oral cavity and pharynx, 
endometrium, pancreas, and colon (Steinmetz & Potter, 1997). The fibre found in 
vegetables and fruit as well as in grain products has been specifically associated with 
prevention of CRC (Slattery, Curtin, Edwards & Schaffer, 2004). Similarly, it appears 
that allium vegetables (garlic, onion, leeks, and scallions) offer certain properties specific 
to CRC prevention (Fleischauer, Poole & Arab, 2000). In contrast, a high intake of red 
meat, particularly processed meat has been associated with a moderate but significant 
increased risk for CRC (Norat, Lukanova, Ferrari & Riboli, 2002). 
2.1.3 High Rates of Hereditary CRC in NL 
A five-year case control study in NL from January 1999 to December 2003 by 
Green et al. (2007) found genetic evidence to explain why NL has a higher proportion of 
high and intermediate risk CRC families than other Canadian provinces. Almost 4% of 
CRC cases were found to come from families meeting the Amsterdam I or II criteria 
associated with HNPCC and a further 0.9% of cases involved FAP. Meanwhile, 43% had 
a familial link to CRC (see Figure 2). 
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52.4% 
Familial Cases 
•HNPCC 
OFAP 
D Sporatic Cases 
Figure 2: The fractions of familial and hereditary CRC cases in NL. Note. Adapted with 
permission from Green et al. (2007) study. 
NL is among the most valuable populations for studying genetics because of how 
the province was settled. Until very recently little immigration or out migration has 
occurred and many large families have remained geographically isolated and religiously 
segregated around a core community for generations. This makes the identification of 
founder effects of disease including the discovery of multiple distinct gene isolates 
associated with CRC more easily identified (Stuckless et al., 2007). 
2.2 CRC Screening 
CRC is a good candidate for screening for several reasons: (i) high incidence, 
prevalence and cause of death worldwide; (ii) the long period between the development 
of polyps and of an invasive cancer (approximately 10 years); (iii) AP are well managed 
by endoscopic intervention; and (iv) survival depends on the stage ofthe tumour (early 
stage leads to better prognosis) (Labianca, Beretta, Mosconi, Milesi & Pessi, 2005). A 
systematic review was done by Pignone, Saha, Hoerger and Mandelblatt (2002) for the 
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US Preventive Services Task Force to measure the impact of CRC screening. The review 
included MEDLINE and the British National Health Service Economic Evaluation 
Database from January 1993 through September 2001. Results showed that mortality 
associated with CRC was significantly reduced with screening for adults 50 years of age 
or older as compared to no screening. The cost per life year saved was estimated at 
$10,000 to $25,000 which is comparable to other commonly endorsed preventive health 
care interventions such as mammography for women older than 50 years of age, or 
treatment of moderate hypertension (Pignone et al., 2002). The data did not suggest 
whether one screening strategy was superior to another. 
2.2.1 Screening Tests 
Four tests are commonly used to screen for CRC: FOBT, flexible sigmoidoscopy 
(FS), colonoscopy and double contrast barium enema (DCBE). In the last decade, the 
number of tests available for CRC screening has increased. This growth has been 
accompanied by changing patterns in the proportion of adults using different tests. In the 
US, rates ofFS are declining, colonoscopy rates are increasing, use ofFOBT remain 
somewhat constant, and the use of DCBE is now becoming very uncommon (Levin et al., 
2008). Details of the different screening tests are discussed below and more specific 
performance characteristics of each are outlined in Appendix B. 
2.2.1.1 Fecal occult blood test 
The main appeal to the FOBT is that it can be done by the family physician or by 
the patient. It is the best studied screening test for CRC but it is also among the least 
sensitive of the tests (Leddin et al., 2004). Sensitivity refers to the probability that the test 
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will correctly detect the presence of disease or condition (Lazarus, 1999). While it is 
designed to detect blood in the stool that is not visible to the naked eye, the presence of 
blood does not necessarily mean cancer. For example, bleeding could be caused by a non-
cancerous condition. Conversely, CRC tumours often bleed intermittently and/or blood 
may not be present throughout the entire stool and would therefore be missed in the 
sample (Alberta Cancer Board, 2008). 
Three large randomized controlled trials on the FOBT have demonstrated that 
cancer is detected at an earlier and more curable stage among patients screened by FOBT 
than unscreened patients (Hardcastle, Chamberlain, Robinson, Moss, Amar, Balfour, et 
al., 1996; Kronborg, Fenger, Olsen, Jorgensen & Sondergaard, 1996; Mandel, Bond, 
Church, Snover, Bradley, Schuman, et al., 1993). Over an eight to 13 year period three 
studies were able to demonstrate a 14% to 18% reduction in CRC deaths with biennial 
screening (Hardcastle et al., 1996; Kronborg et al. , 1996) and a 33% reduction in deaths 
with annual screening (Mandel et al., 1993). 
2.2.1.2 Flexible sigmoidoscopy 
FS can detect polyps located in the left distal end of the colon (the sigmoid colon). 
It is possible to take a biopsy and remove polyps if necessary and since anesthesia or 
sedation is generally not required, non-specialists (including nurses) if adequately trained, 
can provide this procedure in an office-based setting (Levin et al., 2008). In NL, FS may 
be performed by gastroenterologists, general general surgeons, internists, pediatricians, 
casualty officers and general practitioners (Dr. R. Young, Registrar with the College of 
Physician and Surgeon ofNL, personal communication, July 27, 2009). 
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Two case control studies of the FS procedure found a 60% to 80% reduction in 
CRC mortality for the area of the colon within the reach of the scope (Selby, Friedman, 
Quesenberry & Weiss, 1992; Newcomb, Norfleet, Storer, Surawicz & Marcus, 1992). 
Other evidence suggests that the FS is only 60% to 70% as sensitive for advanced 
adenomas and cancers in the colon as the colonoscopy (Imperiale, Wagner, Lin, Larkin, 
Rogge, Ransohoff, et al. 2000; Lieberman & Weisse, 2001). However, sensitivity ofFS is 
speculated to change with age and become even less when screening an older population 
as neoplasms in the proximal region of the colon become more common after 65 years of 
age (Levin, Palitz, Grossman, Correll, Finkler, Ackerson, et al. , 1999). 
Combining FOBT and FS has been proposed as a means of correcting some of the 
limitations of each method used alone. In a randomized control trial with 2885 patients, 
Lieberman and Weisse (200 I) found that FS alone identified 70% of all subjects with 
advanced neoplasia, while combining it with FOBT increased those identified to 76%. 
2.2.1.3 Colonoscopy 
Colonoscopy is the most specific and sensitive of the tests. This means that not 
only is the probability high that it will correctly detect a particular disease or condition 
when it does indeed exist, but it is also highly likely to correctly indicate a negative test 
result when the condition is absent (true negative) (Lazarus, 1999). Such accuracy allows 
for a prolonged screen interval of approximately ten years after a normal test result 
(Leddin et al., 2004; Health Canada, 2002). Colonoscopy allows for direct visual 
examination of the entire colon and rectum and can detect 87-94% of polyps 6-lOmm in 
size (Huang, Lal & Farraye, 2004). Similar to the FS, biopsies and polyp removal can be 
performed if necessary. Colonoscopy does carry a small but potentially very serious risk 
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of perforation and bleeding (approximately 1: 1 000 to 1 :2000 cases) which can, in rare 
cases, result in fatalities (Leddin et al. 2004). It also requires full bowel preparation and 
sedation, making it the most inconvenient of the all the screening tests. 
Two cohort studies suggest that screening with colonoscopy reduced CRC 
incidence by 90% among people with AP (Winawer, Zauber, Nah Ho, O' Brien, Gottlieb, 
Sternberg, et al., 1993; Citarda, Tomaselli, Capocaccia, Barcherini, Crespi & T.I.M.S. 
Group, 2001). Among HNPCC mutation carriers, colonoscopy surveillance has been 
shown to reduce the risk of CRC by more than half, and reduce morbidity and mortality 
by about 65% (Vasen, Taal, Nagengast, Griffioen, Menko, Kleibeuker, et al., 1995; 
Jarvinen, Aarnio, Mustonen, Aktan-Collan, Aaltonen, Peltomaki, et al., 2000). These 
results are despite the 0.2% risk of perforation (Gatto, Frucht, Sundararajan, Jacobson, 
Grann & Neugut, 2003). 
2.2.1.4 Double contrast barium enema 
DCBE is an x-ray that examines the whole colon and rectum. It is cheaper and 
has a lower complication rate than colonoscopy but requires full bowel preparation. There 
have been no randomized controlled trials evaluating its effectiveness in reducing 
incidence or mortality from CRC and no case-control studies evaluating its performance. 
One study by Rex, Rahmani, Haseman, Lemmel, Kaster and Buckley (1997) examined 
medical records of 2193 consecutive CRC cases that were identified in 20 central Indiana 
hospitals. The researchers found the relative sensitivity for detecting CRC was 82% for 
the DCBE as compared to colonoscopy which was 95%. This test is decreasing in 
popularity because a colonoscopy is necessary in follow-up if any polyps or cancers are 
found. 
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2.2.2 Quality Indicators 
Appropriate preparation for all screening tests increases the ability to perform a 
complete examination while inappropriate preparation is a major contributor to costs 
(Rex, Petrini, Baron, Chak, Cohen, Deal, et al., 2006). While quality indicators for 
endoscopy procedures (i.e., colonoscopy, FS, gastroscopy, etc.) have been proposed, data 
are not routinely collected or reviewed. There is also currently no national standard for 
credentialing in gastrointestinal endoscopy (Hilsden, Tepper, Moayyedi & Rabeneck, 
2007). As a result, different groups of physicians who provide endoscopy in Canada can 
undergo quite different training. Many sub-specialists (i.e., gastroenterologists and 
colo rectal general surgeons) complete an accredited training program that includes 
extensive training and practical experience in endoscopy while other specialists (i.e., 
general internists and general general surgeons) receive less training (Hilsden et al. , 
2007). Approximately 100 colonoscopies or gastroscopies annually have been associated 
with a significant improvement in the rate of completion (Wexner, Garbus & Singh, 
2001 ). Schulz, Vinden, and Rabeneck (2007) found that more than 25% of all physicians 
performing colonoscopies in Ontario between April 1, 2001 and March 31 , 2002 
performed less than 100 procedures. 
In the US, a Quality Assurance Task Group of the National Colorectal Cancer 
Roundtable developed a reporting system for colonoscopy which is based on previously 
published continuous quality-improvement indicators (Lieberman, Nadel, Smith, Atkin, 
Duggirala, Fletcher, et al. , 2007). The National Health Service (NHS) in the UK 
evaluates colonoscopists involved with their National Bowel Cancer Screening program 
through a regular practice audit that includes observation of two colonoscopies by triplet 
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video. Quality indicators include completion rates, adenoma detection rates, and correct 
identification of tumor location. In terms of safety measurement, indicators include 
perforation rates, post-polypectomy complications (such as bleeding and perforation), and 
rates of complications requiring hospital admission (Canadian Institute of Health 
Research {CIHR}, 2006). 
2.2.3 CRC Screening Recommendations 
CRC guidelines in Canada have been developed for general (average-risk) 
population which includes adults 50 years of age and older without other known risk 
factors for the disease aside from age (Health Canada, 2002; Leddin et al., 2004). Current 
Canadian guidelines include FOBT every other year, FS every five years, FS combined 
with FOBT every five years, DCBE every five years, or colonoscopy every ten years. 
US guidelines are slightly different for the same groups of patients. Most recently, 
the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer and 
the American College of Radiology came together to develop a collaborative set of 
guidelines to test for AP and cancer. Current US recommendations include FS every five 
years, colonoscopy every 10 years, DCBE every five years or computed tomographic 
colonography every 5 years. To test for cancer specifically, they suggest annual FOBT, 
annual fecal immunochemical test, or stool DNA test (Levin et al., 2008). 
At present, there is no Canadian consensus on screening of high risk familial or 
hereditary CRC populations. The Canadian Association of Gastroenterology and the 
Canadian Digestive Health Foundation have drawn from guidelines produced by the 
American Gastroenterology Association and the British Society of Gastroenterology 
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(Leddin et al., 2004). Meanwhile, certain provinces have released their own clinical 
practice CRC screening guidelines. Alberta's guidelines, for example, include a uniform 
and consistent list of evidence-based CRC screening recommendations for both the 
general (average risk) and high risk CRC populations (Alberta Cancer Board, 2008) (see 
Appendix C). 
2.2.3.1 Organized screening programs 
Compared to opportunistic or ad hoc screening, population-based CRC screening 
through an organized screening program is considered more effective and cost-efficient 
and improves adherence to screening recommendations (CCS, 2009d). Cancers with 
sufficient evidence for population-based screening include cervical, breast and CRC. 
Because screening subjects apparently healthy individuals to potential risk, it is only 
recommended when: 
a) the screening test has been shown to reduce mortality; 
b) the screening test is able to detect the disease in a pre-clinical phase; 
c) the test is highly sensitive and specific; 
d) the test is considered safe and does not subject an individual to an unacceptable; 
level of risk; and 
e) if a cancer is identified through screening, effective treatment is available 
(Labianca et al., 2005). 
When these criteria are met there are several other factors to be considered before 
full implementation of a screening program. This includes the acceptability of the test to 
the individual, costs of the test, and the extent to which there is sufficient capacity in the 
health care system to not only perform the screening test but also to provide the necessary 
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follow-up diagnostic confirmation and treatment for those with abnormal test results 
(Labianca et al., 2005). 
In 2006, following a 6 year pilot project in England (Warwick and Coventry) and 
Scotland (Dundee), the NHS in the UK rolled out its National Bowel Cancer Screening 
Program. Emphasis was placed on wait times, the number of accredited colonoscopists to 
provide timely colonoscopy, maintenance of colonoscopists' workload at a minimum of 
200 colonoscopies per year, and the ability to offer all patients a colonoscopy within two 
weeks of a nurse positive clinic appointment (CIHR, 2006). The Program currently 
centres around five hubs and each is connected to a series of services including screening 
facilities, local hospitals and cancer centre where the planning takes place for associated 
treatments such as pathology, surgery, further imaging, oncology and palliative care. 
Maximal screening capacity has been set at screening 2.5 million individuals between the 
ages of 60 and 69 per year. In addition, the single system entry database provides an 
excellent platform for conducting research. 
In Canada, The Canadian Partnership Against Cancer Screening Action Group 
(2002) recently established a CRC screening network to provide a national forum to 
review, discuss and take action to enhance and improve CRC screening in Canada 
(http://www.partnershipagainstcancer.ca). Although Health Canada has been 
recommending population-based CRC screening programs since 2002 for all adults over 
50 years of age, only in the last few years have provinces begun to explore this. In March 
of2007, Alberta announced its plan to establish a provincial CRC screening program 
involving $500 million from the Alberta Cancer Prevention Legacy Fund. This program 
is to be rolled out over 5 years with an intensive education campaign and research focus. 
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Ontario launched its $193 million province-wide ColonCancerCheck program in April 
2008 and Manitoba is proceeding with its CRC screening program that is borrowed 
heavily on methodology that has proven successful in the UK (Lett, 2007). 
In NL, there is a Screening Working Group of the Provincial Cancer Control 
Strategy (CCS, 2006) which aims to provide strategic direction for improving CRC 
screening services for Newfoundlanders and Labradorians. The Working Group 
recommends many of the core components of an organized cancer screening program 
including: quality control/ quality assurance measures; organized follow-up; education 
and training for both the public and health professionals; program evaluation; information 
systems; and an accurate and up to date cancer registry (CCS, 2009d). The Screening 
Working Group specifically recommends that a "screening division" be created within the 
Provincial Cancer Care Program to ensure adherence to the core components (CCS, 
2006). 
2.3 Barriers to Screening 
Despite evidence that suggests routine screening reduces incidence, morbidity and 
mortality associated with CRC, screening in Canada remains suboptimal (Rabeneck & 
Lawrence, 2004). Barriers exist at the patient, health provider and health care system 
level and all contribute to the underutilization of CRC screening (Beeker, Kraft, 
Southwell & Jorgensen, 2000; Klabunde, Vernon, Nadel, Breen, Seeff & Brown, 2005). 
Barriers include lack of awareness of CRC or screening among the public, inconsistencies 
in screening recommendations, lack of physician encouragement and patient-physician 
interaction, inadequate social support, negative attitudes toward the screening preparation 
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and procedure, and lack of access to health care (Beeker et al., 2000; Klabunde et al., 
2005; Hilsden, McGregor, Murray, Khoja & Bryant, 2004b). 
2.3.1 Adherence Rates 
The 2003 CCHS 2.1 survey data indicated that only 30% of Canadians 50 years of 
age and older received FOBT and/or endoscopy in compliance with CRC screening 
guidelines, whereas 58% had never received either procedure (Sewitch, Fournier, Ciampi 
& Dyachenko, 2007). As depicted in Figure 3, the proportion of people who reported up-
to-date CRC screening was highest in Ontario (20.0%) and lowest in NL (12.6%). As few 
as 4% of women in NL reported having a FOBT within the last two years from when the 
survey was conducted (Zarychanski et al. , 2007). Most recently, McGregor, Hilsden, Li, 
Bryant, and Murray (2007) determined rates of CRC screening among adults aged 50 to 
74 years in Alberta three years after Health Canada released screening guidelines in 2002 
for the general (average risk) population. Findings suggested that women were more 
likely than men to have been screened with a home FOBT whereas men had slightly 
higher rates of screening endoscopy (FS or colonoscopy) in the previous five years. 
Overall, only 14.3% (n = 1476) of the participants were up-to-date on CRC screening. 
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Figure 3: Proportion of survey respondents who reported up-to-date CRC screening by 
Canadian province. Note: From Zarychanski et al. (2007). Used with permission of the 
author. 
Similar to Canada, the rate of CRC screening in the US is low (Shapiro, Seeff & 
Nadel, 2002; Meissner, Breen, Klabunde & Vernon, 2006; Seeff, Nadel, Klabunde, 
Thompson, Shapiro, Vernon, et al. 2004). The National Health Interview Survey (NHIS), 
a longitudinal national survey of households in the US, is the primary source of 
information on the health status of its non-institutionalized population. Findings from the 
NHIS 2000 study found only 45% of men and 41% of women aged 50 years or older had 
undergone FOBT and endoscopy (FS or colonoscopy) within recommended time intervals 
(Seeff et al., 2004). Shortly thereafter, NHIS data from 2003 found that rates had only 
increased minimally to 46% of men and 43% of women (Meissner et al., 2006). This 
slight increase among both men and women was attributed primarily to the increased use 
of colonoscopy as the screening test (32.2% and 29.8 %, respectively) as compared to the 
use ofFOBT (16.1% and 15.3%, respectively) or FS (7.6% and 5.9% respectively). 
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The rate of CRC screening is the lowest among the cancers for which population-
based screening is recommended (CCS, 2009d). Even prostate cancer screening rates 
using prostate-specific antigen (PSA) is higher than CRC screening rates, despite lack of 
evidence supporting population-based screening measures (Lemon, Zapka, Puleo, 
Luckmann & Chasan-Taber, 2001). As described by Lemon and colleagues (2001): 
The designation of breast cancer as a national public health priority, a major 
cancer control research initiative, promotion by public advocacy groups, studies 
confirming the effectiveness of screening, development of supportive state 
policies and legislation, wide promulgation of practice guidelines and widely 
promoting health plan and physician performance standards have all played 
important roles (p. 1265). 
For prostate cancer screening, Lemon and colleagues (2001) feel that while the 
effectiveness of PSA screening on improving survival continues to be debated, the low 
cost and ease of performance are believed to be acceptable features of the test and thus 
influence uptake. 
The public' s reluctance to have CRC screening has been attributed to the 
relatively new release of guidelines as well as the complexity of the guidelines with 
numerous testing options. Potential confusion among the public as well as family 
physicians has been speculated to contribute to low screening rates (Madlensky, Esplen, 
Gallinger, McLaughlin & Goel, 2003). Moreover, public perception of CRC screening is 
frequently negative and concerns about test preparation requirements, pain and 
embarrassment are prevalent (Beeker et al., 2000; Klabunde et al. , 2005). 
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2.3 .1 .1 Physician recommendation 
Physician recommendation plays a large role in patient adherence to CRC 
screening as well as patient acceptance of a particular test regardless of their personal 
preference (Madlensky et al., 2003; Manne, Markowitz, Winawer, Meropol, Haller, 
Rakowski, et al., 2002; Ramji, Cotterchio, Manno, Rabeneck & Gallinger, 2005; 
Klabunde et al., 2005; Seeff et al. 2004; Zapka, Puleo, Vickers-Lahti, & Luckmann, 
2002). In a recent US national survey, primary care physicians reported relatively low 
volumes of ordering, performing or referring for CRC screening (Klabunde et al., 2005). 
This demonstrates that all eligible patients in their practices are not receiving screening. 
Among Alberta primary care physicians, 38% agreed that CRC screening was a lower 
priority than other health issues because oftime restrictions during a routine physical 
examination (McGregor, Hilsden, Murray & Bryant, 2004). It is speculated that family 
physicians may not be encouraging CRC screening because of the lack of reimbursement 
specifically for CRC screening and for referring to specialists (McGregor et al , 2007). 
2.3 .1.2 Physician knowledge and practice patterns 
A survey by Schroy, Barrison, Ling, Wilson and Geller (2002) found that 
gastroenterologists were more knowledgeable than family physicians about eliciting 
family history of CRC and implementing appropriate screening strategies. For example, 
gastroenterologists were more likely than family physicians to suggest the appropriate age 
of25 to begin screening for HNPCC (73% vs. 43%) and the appropriate screening test, 
the colonoscopy (97% vs. 76%). A similar study by Barrison, Smith, Oviedo, Heeren and 
Schroy (2003) found that family physicians both in practice and in training were 
knowledgeable about existing screening recommendations for individuals with a family 
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history ofCRC, but not AP. However, both groups lacked the necessary knowledge and 
risk assessment skills to appropriately screen individuals with or at risk for F AP and 
HNPCC. 
Between October 2004 and March 2005, self administered questionnaires were 
distributed by Sewitch, Burtin, Dawes, Yaffe, Snell, Roper, et al. (2006) to 65 family 
physicians and gastroenterologists at three university affiliated hospitals in Montreal, 
Quebec. All respondents knew about the screening guidelines for the general (average 
risk) population and 95% said they were screening as suggested. Among those who 
screened, most preferred FOBT (88.3%) and colonoscopy (88.3%) rather than FS (10.0%) 
or DCBE (30.0%). Most family physicians knew the correct screening frequency for 
FOBT (87.6%) but less than 40% could identify correct screening frequency for the other 
modalities. Meanwhile, an Alberta study by McGregor and colleagues (2004), found that 
less than half(41.9%) of primary care physicians (n = 595) were familiar with the CRC 
screening guidelines. Seventy- four percent of the physicians recommended that 
asymptomatic patients undergo screening, however only 35.6% offered screening to at 
least 75% of general (average-risk) patients. Few (9.4%) rated FOBT as an "excellent or 
very good" screening test and most (64.1 %) would choose colonoscopy, if they 
themselves were to undergo screening. 
It is well documented in the literature that genetic testing is associated with 
increased adherence to screening guidelines for the high risk CRC population (Wagner, 
van Kessel, Kriege, Tops, Wijnen, Vasen et al., 2005; Halbert, Lynch, Lynch, Main, 
Kucharski, Rustgi, et al., 2004; Hadley, Jenkins, Dimond, de Carvalho, Kirsch, Palmer, et 
al., 2004). However, this requires that physicians are aware of diseases with defmed 
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genetic linkages and are knowledgeable of the importance of involving genetic counselors 
to ensure that appropriate information is communicated to patients. A study by Giardiello, 
Brensinger, Petersen, Luce, Hylind, Bacon, et al. (1997) found that among physicians 
across 32 states in the US who requested genetic testing for patients with F AP, more than 
80% did not offer genetic counseling before the test or obtain informed consent for 
testing. Additionally, in 31.6% of cases, the physicians misinterpreted the test results. A 
similar study in New York State by Batra, Valdimarsdottir, McGovern, Itzkowitz and 
Brown (2002) found that 99% of gastroenterologists obtained a family history from their 
patients when screening for CRC and 95% were aware of cancer genetic counseling. 
However, only 51% would routinely refer patients for genetic counseling before 
providing cancer predisposition testing. In addition, only 52% were aware of the 
availability of genetic testing for F AP and 34% for HNPCC. 
2.3 .1 .3 Patient knowledge and attitudes 
Attitudes and knowledge towards CRC screening among adults have been 
investigated quantitatively and qualitatively. A study by Shokar, Vernon and Weller 
(2005) conducted in-depth individual interviews (n = 30) with individuals 50 years of age 
or older, from diverse ethnic backgrounds. All participants, particularly minority 
participants, lacked knowledge of cancer, CRC and screening. Participants demonstrated 
difficulty understanding terms routinely used in practice, which the authors concluded 
underlie the challenges providers face in effectively discussing cancer and CRC screening 
recommendations with patients. Additionally, there was a lack of understanding about the 
concept of screening and that screening is performed when a person feels well. Another 
study by Janz, Wren, Schottenfeld, and Guire (2003) conducted telephone interviews (n = 
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355) with men and women, aged 50 to 79 years of age living in Michigan State. Less than 
30% of participants were found to be adherent to the current screening guidelines. 
Reasons given were the belief that the screening test is not needed and that it is 
embarrassing. 
In 2004, a series of focus groups was conducted in Ontario with several groups 
including the general (average risk) population, individuals with a personal or family 
history of CRC, and family physicians. The purpose was to help inform the Ontario 
Expert Panel on CRC Screening and to assist with preparation of their proposal for a 
provincial CRC screening program (Goel, Gray, Chart, Fitch, Saibil & Zdanowicz, 2004). 
Among the general (average risk) participants, there was limited experience with 
colonoscopy and it was not perceived to be a test that would be acceptable for screening. 
However, those who had already experienced colonoscopy were more willing to accept it 
and most agreed they would only be willing to go for the test if they had symptoms. The 
main concerns raised about colonoscopy included risks ("piercing") and pain that might 
be associated with it. Otherwise, the majority of general (average risk) participants chose 
FOBT as the preferred screening test. The higher risk participants felt that the onus to 
promote screening should be with the physician who should also explain the test in detail. 
They felt that education of physicians was important and the way screening is done 
should be standardized across all physicians. 
People who practice other healthy behaviors have been found to be more likely to 
pursue CRC screening (Shapiro et al., 2002). For example, women who underwent a 
mammogram or pap smear test within recommended intervals appeared more likely to 
report having undergone CRC screening compared with those who did not (Seeff et al. , 
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2004). Individuals aware oftheir risk for CRC, particularly if notified through an affected 
family member (i.e., first degree relative affected with CRC) also appeared more likely to 
be screened (Lemon et al., 2001 ; Seeff et al., 2004; Manne et al., 2002). And finally, 
socio-demographics, including male sex (Sewitch et al. , 2007; Brawarsky, Brooks & 
Mucci, 2003) and highest income level (Sewitch et al., 2007; Whynes, Frew, Manghan, 
Scholefield, & Hardcastle, 2003) have been associated with increased adherence to FOBT 
screening guidelines. 
2.3.1.4 Health system barriers 
Widespread implementation of CRC screening strategies in the past have been 
limited because of extended wait times for gastroenterology specialist care for patients 
with digestive diseases (Hilsden et al. , 2007). This includes access to trained endoscopists 
who perform colonoscopies. In 2002, physician socio-demographic and activity data were 
obtained by Hilsden et al. (2007) from the Canadian Institute of Health Information' s 
National Physician Database. Gastroenterologists and general surgeons performed over 
97% of all colonoscopies. Gastroenterologists were the primary providers of 
colonoscopies in larger urban areas, whereas general surgeons were the primary providers 
in smaller urban and rural areas. Annually, an average of317 colonoscopies was 
performed by each general surgeon, 516 by each gastroenterologist, and 203 by other 
physicians. 
Recently, national guidelines were set by the Canadian Association of 
Gastroenterology regarding accepted wait times for specialist gastroenterology care in 
Canada (Paterson, Depew, Pare, Petrunia, Switzer, et al., 2006). A study by Leddin, 
Armstrong, Barkun, Chen, Daniels, Hollingworth and colleagues (2008) found that less 
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than one-half of the patients referred received a full evaluation within the suggested wait 
time. Canada is currently facing a national shortage of gastroenterologists, 33% of whom 
are expected to retire within the next 10 years. Based on the number of new 
gastroenterologists currently being trained, this would result in an estimated 10% 
reduction of gastroenterologists within 10 years time (Moayyedi, Tepper, Hilsden & 
Rabeneck, 2007). As described by Hildsen (2004a), these statistics are concerning when 
provinces such as Alberta are experiencing a colonoscopy rate that more than doubled 
(146% increase) from 1994 to 2002. 
Canada currently has fewer gastroenterologists per 100,000 population than the 
US, France or Australia (Moayyedi et al., 2007). There is no definition of what the 
optimum number of gastroenterologists per 100,000 population should be. However, 
merely increasing endoscopy facility resources is not considered an adequate approach to 
meet the colonoscopy demand given that medical and surgical specialists are averaging 
54.5 hours and 57.6 hours of work per week, respectively (Hilsden et al., 2007) 
Alternative care models involving primary care physician endoscopists, nurse 
practitioners, physician extenders such as nurse endoscopists and gastroenterology 
physician assistants have been suggested as a way to meet the rising demand while 
shortening wait times (Rabeneck & Adams, 2006). 
Cotterill, Gasparelli and Kirby (2005) used the rural community ofWawa, Ontario 
to assess if a CRC screening program reliant on colonoscopy could be performed safely 
and effectively by non-specialist endoscopists in rural areas. Two family doctors were 
trained to do the colonoscopies, which were carried out in hospital. A small increase in 
staff and operation room time was required. Patients between the ages of 50 and 75 and 
30 
those at high risk of CRC based on family history were screened. Measures of safety and 
effectiveness were monitored. In two years of screening, one of 152 patients was found to 
have CRC and 23.7% had AP. There were no complications. Rates ofCRC and 
adenoma detection were similar to rates found in other screening programs, suggesting 
that non-specialists can safely perform colonoscopies while better meeting the demands 
for CRC screening in rural communities. 
Overuse of colonoscopy is also a potential problem to providing services within a 
timely fashion. The American Society for Gastroenterology Endoscopy {ASGE} (2006) 
and the US Multi-Society Task Force on Colon Cancer has published appropriate 
indicators for colonoscopy (Rex et al., 2006). A study by Minoli, Meucci, Bortoli, 
Garripoli, Gullotta, Leo, et al. (2000), attempted to evaluate the appropriate use of 
colonoscopy in the public health system in Italy and to assess whether the ASGE 
guidelines are useful in clinical practice. Approximately 21% of colonoscopy 
examinations requested were not indicated according the ASGE guidelines. A similar 
scenario appears to be occurring in Ontario, as FS rates have declined over past decades 
due to gastroenterologists and general surgeons preferring to do colonoscopies (Rabeneck 
& Adams, 2006). 
2.3.2 Adherence to Repeat Screening 
To achieve the goal of reducing cancer morbidity and mortality, it is imperative 
that patients receive timely and appropriate follow-up. It is also important that they have 
positive experiences when accessing the health system to prevent deterrence from the 
screening process (Geary et al., 2007). Adherence is especially difficult for colonoscopy 
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because of its rather invasive nature and the requirement for sedation (Goel, et al. 2004). 
While HNPCC gene mutation carriers in NL were able to identify the benefits of 
engaging in regular screening, the demands of scheduling appointments and waiting for 
results were identified as being overwhelming, confusing and time consuming. Follow-up 
monitoring by health care providers was considered critical to successful coping and 
overall adjustment to the disease. (J. Stokes, Research Coordinator, personal 
communication, October 21 , 2008). 
A Finnish study aimed at evaluating the compliance and satisfaction of HNPCC 
gene mutation carriers adjusting to a life of colonoscopy screening found a compliance 
rate that was extremely high (99.5% in the study group) (Pylvanainen, Kairaluoma, & 
Mecklin, 2006). Part of the reason was attributed to the comprehensive face-to-face 
counseling and continuous communication arranged with a professional from the Finnish 
HNPCC Registry. Another reason was attributed to the large number of neoplastic lesions 
that were discovered during follow-up. Similarly, a recent Swedish study involving 240 
persons in long-term CRC surveillance, including 28 HNPCC mutation carriers, found 
that individuals who recalled detection of polyps in the past had an improved perception 
of the benefit behind screening, thus increasing patient motivation to take-up surveillance 
endoscopies (Liljegren, Lindgren, Brandberg, Rotstein, Nilsson, Hatschek, et al., (2004)). 
Other positive influences on adherence to repeat screening have been 
demonstrated in a California-based study by Bastani, Yabroff, Myers, and Glenn (2004) 
who examined follow-up among women with abnormal pap tests. This study found that 
reminders delivered by mail or telephone as well as education to address fears related to 
an abnormal fmding through telephone counseling, pamphlets or other material were 
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largely successful in improving timely follow-up. Another study also conducted in 
California by Engelstad, Stewart, Nguyen, Bedeian, Rubin, Pasick, et al. (2001) found 
that a specialized clinic involving a nurse case manager, tracking system, reminder calls, 
rescheduling of missed appointments, and clinic staffing with on-site colposcopy also 
achieved a significantly increased follow-up rate among women with abnormal pap tests. 
Same day follow-up has also been successful in increasing follow-up rate for an abnormal 
pap tests and colposcopy (Holschneider, Felix, Satmary, Johnson, Sandweiss, & Montz, 
1999) as well as for abnormal colonoscopy and flexible sigmoidoscopy (Stem, Fendrick, 
McDonnell, Gunaratnam, Moseley, & Chey, 2000). In the latter study, when patients 
were asked their preference for future screening, 96% chose same day and same site 
follow-up colonoscopy. 
Finally, the impact of patient navigators has been assessed by Nash, Azeez, 
Vlahov, and Schori (2006) in assisting patients obtaining both initial and follow-up 
colonoscopy screening. The purpose of the patient navigators was to increase efficiency 
and provide continuity for the patients at various points from time of referral to the 
completion of the colonoscopy procedure. The patient navigators assisted in completing 
paper work, scheduling appointments and providing appointment reminders. They were 
able to facilitate referrals either through the gastrointestinal or colorectal clinic. The 
likelihood of the patient keeping the appointment for colonoscopy after the patient 
navigator intervention increased by nearly three-fold. For those seeking the procedure for 
screening purposes, rates increased from 56.8 per month to 119 per month. 
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2.4 Summary 
CRC is one of the most prevalent yet preventable forms of cancer. With CRC 
incidences in NL being approximately twice that of British Columbia and rates only 
expected to increase with the aging population, adherence to screening guidelines needs 
to be improved. This requires that family physicians and specialists are not only 
knowledgeable of CRC risk factors and screening guidelines but are also selective in the 
type of screening test so not to exhaust available resources, namely for colonoscopy. As 
described in this literature review, an organized and well coordinated approach to 
screening has been shown to improve rates of adherence to screening guidelines. 
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Chapter Three -Methodology 
This descriptive, cross-sectional study profiles specific characteristics of 
colonoscopy service providers in NL. A 20 question self-administered survey (see 
Appendix D) is used to collect infonnation about the knowledge and practice patterns of 
gastroenterologists and general surgeons regarding screening patients who have a 
personal or family history of CRC or AP and those with a genetic predisposition for 
HNPCC or FAP. It also describes their attitudes about current CRC screening services in 
the province. This infonnation will help to address the ultimate objective of the study 
which is to infonn and guide a comprehensive long-tenn strategic plan to manage CRC 
screening in NL, particularly for the higher risk populations. 
3.1 Survey Development 
Questions are modeled after a previously administered survey to physicians and 
specialists which covered similar content (Schroy et al., 2002). This is done to increase 
the validity and reliability of the findings while allowing for a comparison of findings. 
Questions are designed to reflect published CRC screening guidelines (Alberta Cancer 
Board, 2008; Leddin et al. , 2004; Levin et al., 2008). Experts consulted during the 
development of the survey instrument include the Chair of Surgery for the Faculty of 
Medicine at Memorial University, a Medical Geneticist, a Medical Ethicist and a 
Professor in Health Policy/ Health Care Delivery. These individuals offered unique 
perspectives on the types of questions required to adequately address the research 
objectives. 
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The survey is divided into three sections: 1) specialist personal and practice 
characteristics, 2) hereditary CRC screening, and 3) attitudes about current CRC 
screening services. The majority of questions are closed-ended and involve clinical 
scenarios with the option to check more than one answer. Definitions of family history of 
CRC and AP are provided. Family history of CRC is defined as having a single first-
degree relative with CRC diagnosed at younger than age 55. Family history of AP is 
defined as having a single first-degree relative with AP diagnosed at younger than age 60 
(Schroy et al., 2002). 
In the first section of the survey, the specialists are asked questions related to 
basic demographics including specialty, gender, age, year of graduation, years of practice 
in NL, professional body certification and community size (Questions # 1-6). They are 
asked ifthey perform colonoscopies in their practice, and if so, for how many years and 
how many annually (Question# 7-9). This information helps to identify the relative 
distribution of available gastroenterologists and general surgeons who provide 
colonoscopies across the province. 
In the second section ofthe survey, the specialists are asked if they routinely ask 
asymptomatic patients (both under 40 years and over 40 years of age) about family 
history of CRC or AP. This is followed by specific sub-questions about screening 
practices for patients with: 1) family history ofCRC; 2) family history of AP; 3) FAP, 4) 
HNPCC; and 5) asymptomatic patients 50 years of age and older with no family history 
of CRC or AP. Questions pertain to the age they recommend to begin screening, the type 
of screening modality, other health professionals involved and if genetic testing is 
routinely recommend for patients suspected of being carriers of HNPCC or F AP gene 
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mutations (Questions# 12-13). The specialists are asked ifthey discuss 
advantages/disadvantages associated with different screening approaches with their 
patients, and if yes, whether they give patients the opportunity to apply their own 
preference to the type of screening test used (Question #14). They are also asked who 
they feel should be responsible for monitoring patient compliance to screening, if and 
how they prioritize care, and expected wait times for their colonoscopy service 
(Questions# 15-17). The prioritization question(# 16) is open-ended as it was felt to be 
unique for each specialist, particularly those practicing in rural regions. This section 
concludes with a question about where the specialists have obtained information 
pertaining to CRC risk factors and screening recommendations and their preferred 
method of receiving such information (Question # 18). 
In the final section of the survey a five-point Likert scale is used to measure 
attitudes about current CRC services in NL (Question# 19). This includes questions 
related to: the need for a province wide CRC registry; the need for a province wide CRC 
screening central booking centre; whether gastroenterologists, general surgeons and 
family physicians could use more education about familial and hereditary CRC screening; 
the usefulness of genetic testing to their practice; and whether health professionals other 
than gastroenterologists and general surgeons should be trained to perform colonoscopies. 
Finally, the specialists are asked if they would be willing to be contacted for a 
follow-up interview and if they had any additional comments (Question# 20). This 
provides the opportunity for future contact if new themes of interest arise from analysis of 
the data. 
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3.1.1 Pretesting 
The survey was pre-tested with one gastroenterologist and one surgeon at the 
Health Sciences Centre in St. John' s. Feedback was used to improve clarity of questions 
while ensuring appropriate options for answering the different clinical scenarios. As a 
result of the pretesting, an additional option of "do not screen" was added for all clinical 
scenario questions (Question# 12-13). As well, the Likert scale question (Question # 19 c 
and d) regarding gastroenterologist and surgeon attitude about continuing education needs 
which were originally combined into the same question, were separated into two different 
questions following the pretesting. 
3.2 Sample Frame 
The sample frame includes all gastroenterologists and general surgeons registered 
with the College of Physicians and General surgeons ofNL as of December 31 5\ 2008. 
Specialist mailing addresses are available on the College website. To be included in the 
study, specialists indicate on the first page of the survey that they practice in NL and 
perform colonoscopies. Excluded from the study are physicians completing their post 
graduate residency training or whose practice is primarily pediatric patients. 
3.2.1 Representativeness of the sample 
To assess the representativeness of the sample, chi square tests are used to 
compare respondents to non-respondents in terms of specialty, gender and community 
size of practice. These variables are available from College of Physicians and General 
surgeons of NL website allowing for the inference of traits of non-respondents. 
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3.3 Data Collection 
Certain recommendations from the Tailored Design Approach for Mail and 
Internet Survey (Dillman, 2007) are used to maximize response rate. This includes the use 
of a respondent friendly questionnaire, repeat contact (second mailing to non-respondents 
3 weeks after the initial mail-out with replacement questionnaires), return envelopes with 
postage, and personalization of correspondence. Attached to the first page of the survey is 
a cover letter which describes the purpose of the study and its potential impact in helping 
to improve CRC screening services in the province. The specialists are informed that the 
survey will take less than ten minutes to complete, as determined from the pretesting. 
Tracking of responses is done using postcards which are returned separately from the 
surveys (see Appendix E). This approach ensures anonymity of responses. The first round 
of surveys was mailed on January 281h, 2009. 
Due to the relatively small number of specialists performing colonoscopies in NL, 
a few extra steps are taken to further increase response rate. For example, when the 
second round of surveys was mailed on February 21 5\ 2009, a phone call was also made 
to the specialists' respective secretaries. Additionally, the Chair of Surgery for the Faculty 
of Medicine at Memorial University along with a gastroenterologist from the 
Gastrointestinal Unit at Health Sciences Centre in St. John' s reminded colleagues to 
complete the survey. 
3.4 Data Management 
Survey responses are entered into SPSS, a database for statistical analysis. Results 
are entered twice in order to minimize data entry errors (National Statistical Service, 
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2002). Completed surveys are given a unique identifier code so that if data entry errors 
are found, the original survey is easily checked and errors corrected (National Statistical 
Service, 2002). A separate electronic database is used to track the postcards returned, 
which includes respondent identity and mailing address. This is used to determine to 
whom to mail a second survey and follow up. 
Prior to conducting any analysis, the data are cleaned to detect and remove any 
errors, inconsistencies and implausible entries by running frequencies for all questions 
and uni-variate descriptive statistics (mean, median, standard deviation, minimum and 
maximum) to identify any out-of-range values. Depending on responses, certain questions 
are recoded to either condense categories or to add categories based on responses to the 
"other" option. For example, certain respondents indicated they begin screening 
individuals with a family history of CRC at age 40 or ten years before the youngest 
affected family member. However, this option was not provided so the question is 
recoded for analysis. "Additional comments" are also recoded into new variables and 
analyzed for common themes. 
Given the nature of the research objectives, the analysis is limited to descriptive 
statistics. Frequencies are used for categorical variables and means and standard 
deviations are used for continuous variables (e.g. responses using five-point Likert scale). 
Comparisons between groups are not done due to the small sample size and risk of 
potentially identifying individual specialists. Any missing values are excluded from the 
analysis. Missing values for individual questions range from 0 to 3 with most questions 
having no missing values. Details of the coding scheme for variables used in the analysis 
are outlined in Appendix F. 
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3.6 Ethical Considerations 
The survey was reviewed by a Sub-Committee of the Human Investigative 
Committee with the Faculty of Medicine at Memorial University (see Appendix G). Final 
approval was granted on January 6th, 2009. 
Results are reported in aggregate only due to the small sample size. Any question 
that could potentially identify a respondent is avoided (i.e., school of medical graduation 
or specific area of employment). In certain cases categories are re-grouped if there is any 
reason to believe respondents might be identified. As mentioned earlier, tracking of 
respondents' identity and ensuring anonymity is achieved through postcards which are 
returned separately from the surveys. Finally, all completed surveys are stored in a locked 
room with restricted access. Any electronic files of the data are password protected. 
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Chapter Four- Results 
4.1 Survey Response 
There were 58 gastroenterologists and general surgeons listed on the College of 
Physicians and Surgeon ofNL website as of December 2008. Five could not be contacted 
because of an incorrect or missing address as reported on returned surveys or through 
contact with secretaries during follow-up. Nine do not perform colonoscopy and one 
respondent works with the pediatric population and is therefore excluded because the 
majority of questions are not applicable. The final sample frame is therefore reduced to 
43. Of these, 36 returned a survey for an 83.7% response rate (see Figure 4). 
-
Excluded (n = 15) 
• No/incorrect address 
(n = 5) 
• Do not perform 
colonoscopy (n = 9) 
• Pediatric surgeon (n = 1 ) 
'---------------------/ 
/ 
I 
58 Gastroenterologists and 
General surgeons 
/ 
43 Eligible Gastroenterologists 
and General surgeons 
I 
/ 
36 Respondents (83.7%) 7 Non-Respondents 
Figure 4: Determination of study sample and response rate 
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4.2 Representativeness of Sample 
The gender, specialty and community size of the sample frame and respondents 
are compared by calculating chi-square tests by hand (see Table 1). These characteristics 
are selected because data are available (or inferred) from information provided on the 
College of Physicians and General surgeons ofNL website for all specialists in the 
sample frame. Based on the chi square test statistical analysis, the sample is 
representative in terms of gender and specialty but not for community size. The sample 
slightly over represents specialists practicing in a community size of population <1 00,000 
and under represents those practicing in a community size of population > 100,000. 
Table 1 
Comparison of sample frame and respondents to assess representativeness of sample 
Sample Frame Respondents p value 
Gender 
Male 36 (83.7) 29 (82.9) >.05 
Female 7 (16.3) 6 (17.1) 
Specialty 
Gastroenterology 9 (20.9) 9 (25.7) >.05 
Surgery 34 (79.1) 26 (74.3) 
Community Size of Practice 
<10,000 7 (16.3) 7 (20.0) < .05 
10,000-100,000 15 (34.9) 15 (42.9) 
>100,000 21 (48.9) 13 (37.1) 
4.3 Respondent Characteristics 
Table 2 describes respondent characteristics. Gastroenterologists make up one 
quarter of the sample. The majority of respondents are male. There is a fairly even spread 
of years since graduation among the respondents, however more than half of respondents 
have been practicing in NL for less than ten years. Sixty-two percent of respondents work 
in a rural/sub-urban community with a population <1 00,000 and the remainder in an 
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urban community with a population > 100,000, presumably St. John' s. The majority of 
respondents are certified with the Royal College of Physicians and General surgeons. 
Most perform around 250-500 colonoscopies per year and two of the respondents perform 
less than 100 per year. 
Table 2 
Characteristics of specialists who perform colonoscopies in NL 
Specialty n (%) 
Gastroenterology 9 ( 25.0) 
Surgery 27 (75 .0) 
Gender 
Female 6(1 7. 1) 
Male 29 (82.9) 
Years since medical school2raduation * 
less than 1 0 years ago 12 (35.3) 
10-20 years ago 7 (20.6) 
20-30 years ago 8 (23 .5) 
more than 30 years ago 7 (20.6) 
Number of years practicin2 in NL 
less than 10 years 20(57.1) 
10-30 years 12 (34.3) 
more than 30 years 3 (8.6) 
Professional body certification 
Royal College of Physicians and General surgeons ofCanada 29(82.9) 
American Board of Surgery 3 (8.6) 
Non-Certified Specialist 4 (11.4) 
Other 3 (8.4) 
Community size 
Rural (< 10,000) 5 (1 4.3) 
Small urban (l 0,000-1 00,000) 17 (48.6) 
Urban (> I 00,000 population) 13 (37.1) 
Number of years performin2 colonoscopies 
less than 1 0 years 12 (34.3) 
10-30 years 2 1 (60.0) 
more than 30 years 2 (5.7) 
Number of colonoscopies performed annually 
less than I 00 2 (5.9) 
101-250 7 (20.6) 
251 -500 12 (35.3) 
501 -750 6 (1 7.6) 
more than 750 7 (20.6) 
* After releasmg the survey, we not1ced an overlap between the categones. None of the respondents 
indicated more than one category. 
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4.4 Respondent Knowledge and Practice Patterns 
More than three quarters of respondents collect family histories about CRC and/or 
AP from patients greater than 40 years of age (see Table 3). 
Table 3 
Specialists who collect[amilyhistory_from patients withfamily history ofCRC and/or AP 
Percent of patients < 40 years of a2e n(%) 
0-25% 9 (25.7} 
26-75% 4 (11.4) 
76-100% 22 (62.9) 
Percent of patients > 40 years of age 
0-25% 2 (5.7) 
26-75% 5 (14.3) 
76-100% 28 (80.0) 
As shown in Table 4, 40 to 49 years of age or I 0 years earlier than the youngest 
diagnosed family member is the most common age to begin screening patients with a 
family history ofCRC (85%) and AP (69%). Fifteen to 24 years of age is the most 
common age to begin screening patients with F AP (86%) and 25-39 years of age for 
patients with HNPCC (61 %). The preferred screening test for all groups is colonoscopy, 
followed by FS for patients with F AP (22%) and digital rectal exam (DRE) for patients 
with a family history of CRC (20%). For those who selected DRE, most also selected in 
combination FOBT. Although not provided as an option, two of the respondents indicate 
they use oesophago-gastro-duodectomy as a screening test for patients with F AP. 
At least one third of respondents involve family physicians in the screening 
process for their patients. Another one-third of respondents do not include any other 
health professionals in the care of patients with a family history of CRC or AP. It should 
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be noted that it was not possible to determine from the survey which health professionals 
referred the patients to the specialists. 
Genetic testing is routinely recommended by 97% of respondents for patients 
suspected for F AP and by 81% for patients with HNPCC. Of all the respondents, 72% 
involve genetic counselors with the Provincial Medical Genetics Program (PMGP) for 
patients with F AP, while 67% do so for patients with HNPCC. One quarter of 
respondents would also include a gynecologist and/or urologist for patients with HNPCC. 
Colonoscopy every ten years is the most commonly reported screening test used 
with the general (average risk) population which includes adults 50 years with no other 
risk factors for CRC other than age. This is followed by FOBT. For those respondents 
who indicate they use DRE for the general (average risk) population, almost all report 
also using FOBT. Over three-quarters of respondents take the time to discuss the 
advantages and disadvantages of the different screening methods with patients and of 
these, most allow patient preference to influence the screening test used. 
As shown in Table 5, only 15% of respondents report seeing general (average 
risk) individuals for screening with colonoscopy within three months while another one-
third are not seeing them for over a year. Meanwhile, 24% of respondents will see 
patients with a family history of CRC; 30% will see patients with a family history of AP; 
and 56% will see patients with F AP or HNPCC within this same timeframe. 
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Table 4 
Hereditary CRC screening practices (a) family history ofCRC (b) family history of AP (c) 
FAP (d) HNPCC (e) general population 
Family history Family FAP HNPCC General 
ofCRC history of Population 
AP 
n (%) 
Age 
31 
15-24 0 (0.0) I (2.8) (86.1) 12 (35.3) n/a 
25-39 4(11.8) 2 (5.6) 5 (13.9) 20 (58.8) n/a 
40-49 (or 1 0 year before 
youngest affected family 
member} 29 (85.2) 25(69.4) 0 (0.0) 2 (5.9) 
50+ I (2.9) 8 (22.2) 0 (0.0) 0 (0.0) n/a 
Screening test * 
Digital rectal exam 7 (20.0) 5 (13.9) 5 (13.9) 5 (13.9) 5 (13.9) 
Flexible sigmoidoscopy I (2.9) l (2.8) 8 (22.2) I (2.8) 2 (5.6) 
29 
Colonoscopy 33 (94.3) 34 (94.4) (80.6) 34 (94.4) 25 (69.4) 
FOBT 5 (14.3) 5 (13.9) 4(11.1) 4(11.1) 14_(38.9) 
FOBT plus flexible 
sigmoidoscopy 0(0.0) l (2.8) 0 (0.0) 1 (2.8) 2 (5.6) 
Double contrast barium 
enema 2 (5.7) 2(5.6) 2 (5.6) 2 (5.6) 3 (8.3) 
Do not screen 1 (2.9) I (2.8) I (2.8) 1 (2.8) 
Other health 
professionals involved * 
Other gastroenterologists/ 13 n/a 
general surgeons 8 (22.9) 8 (22.2) (36.1) 13 (36.1) 
16 nla 
Family doctor 16(45.7) 14 (38.9) (44.4) 14 (38.9) 
26 n/a 
PMGP 9 (25 .7) 5 (13.9) (72.2) 24 (66.7) 
Gynecology/ Urology I (2.8) 0 (0.0) 3 (8.3) 9 (25 .0) n/a 
None 11 (31.4) 13 (36.1) 2 (5.6) 2 (5.6) n/a 
Genetic testing n/a 
32 n/a 
Yes I (3 .0) 3 (9.4) (97.0) 25 (80.6) 
No 32 (97.0) 29 (90.6) I (3.0) 6 (19.4) nla 
* Responses add up to more than 100% because respondents were allowed to select more than one answer. 
PMGP = Provincial Medical Genetics Program; CRC = colorectal cancer; AP = adenomatous polyps; F AP 
= familial adenomatous polyposis; HNPCC = hereditary non-polyposis colorectal cancer; n/a = not 
applicable (certain questions were not asked about screening for the general population) 
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Table 5 
Reported wait times for a colonoscopy according to patient group* 
General Family history Family history FAP and 
population ofCRC ofAP HNPCC 
n ~%) 
<month 2 (6.1) 2 (5.9) 3 (9.1) 5 (14.7) 
1-3 months 3 (9.1) 6 (17.6) 7 (21.2) 14 (41.2) 
3-6 months 6 (18.2) 9 (26.5) 7 (21.2) 5(14.7) 
6-12 months 11 (33.3) 9 (26.5) 11 (33.3) 9 (26.5) 
>12 months 11 (33.3) 8 (23.5) 5(15.2) 1 (2.9) 
.. CRC = colorectal cancer; AP = adenomatous polyps; F AP = famlltal adenomatous polyposis; HNPCC = 
hereditary non-polyposis colorectal cancer 
*After releasing the survey, we noticed an overlap between the categories. None of the respondents 
indicated more than one category. 
Over three quarters of respondents indicate they have a systematic approach to 
prioritizing their colonoscopy service (see Table 6). Slightly more than half of 
respondents use presenting symptoms as the basis for this prioritization. Of presenting 
symptoms, occult blood in the stool is the most frequently reported. Some of these 
presenting symptoms would presumably be included in the referral letter to the specialists 
(Dr. J. Green, Medical Geneticist at Memorial University, personal communication, June 
13, 2009). 
As shown in Table 7, almost one quarter of respondents feel it is the responsibility 
of the patient to monitor compliance to screening. Another one quarter feel it is the 
responsibility ofthe patient and family physician combined. Meanwhile, 16% of 
respondents feel it is the responsibility of the gastroenterologist and/or surgeon but only 
with the patient and family physician also monitoring. 
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Table 6 
Specialist criteria for prioritiz ing colonoscopy service 
Do you have a systematic approach to prioritization? n(%) 
Yes 28 (80.0) 
No 7 (20.0) 
On what basis do you prioritize? 
Symptoms 19 (52.8) 
Abnormal lab data (i.e. iron deficiency) 4(11.1) 
Occult blood 8 (22.2) 
Change in stool pattern 4 (11.1) 
Weight loss 2 (5.6) 
Abnormal barium enema 2 (5.6) 
Referral from Family Doctor/ Nurse Practitioner 3 (8.3) 
Referral from PMGP/ Results from genetic testing 2 (5.6) 
Family history (CRC, polyps, FAP, HNPCC) 11 (30.6) 
Personal history of CRC or polyps 3 (8.3) 
F AP/HNPCC patients well past their screening interval 2 (5.6) 
Age 4_{11.1) 
.. CRC = colorectal cancer; AP = adenomatous polyps; F AP = fam1llal adenomatous polypos1s; HNPCC = 
hereditary non-polyposis colorectal cancer; PMGP = Provincial Medical Genetics Program 
Table 7 
s . f h ':>pecza zst approac to momtormg 
Who should be responsible? 
Patient 
GIS 
PMGP 
Family Doctor 
Patient + GIS 
Patient + PMGP 
Patient + Family Doctor 
Patient + GIS + Family Doctor 
GIS + Family Doctor 
h d ' ere ztary 
Patient + GIS + PMGP + Family Doctor 
CRC patzents f comp. zance to screenm~ 
n (%) 
8 (22.2%) 
1 (2.8) 
2 (5.6) 
4 (11.1) 
2 (5.6) 
1 (2.8) 
8 (22.2) 
6 (16.7) 
2 _{5.6) 
2 (5.6) 
PMGP = Provmc1al Med1cal Genet1cs Program; G/S = Gastroenterologist/Surgeon 
Almost all respondents (94%) indicate they have heard or read information 
pertaining to risk factors and screening recommendations for hereditary CRC through 
medical journals. This is followed by information on the topic received through hospital 
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rounds (64%) and consultation with colleagues (50%). When asked in an open-ended 
question about the preferred method of receiving this type of information, mail (including 
letters and newsletters) and email/internet is most frequently selected (see Table 8). 
Table 8 
Received and preferred sources of information pertaining to risk factors and screening 
recommendations for hereditary CRC 
Source n (%)* 
Medical journals 33 (94.3) 
Patient letter from PMGP 15 (41.7) 
Patients 8 (22.2) 
Hospital rounds 23 (63.9) 
Colleagues 18 (50.0) 
Text books 2 (5.6) 
Conferences 4(11.1) 
Canadian Association of Gastroenterology 2 (5.6) 
Internet 1 (2.8) 
Endoscopy Unit 1 (2.8) 
Preferred method of receiving this information 
Medical journals 6 (16.7) 
Mail/Letters/Newsletters (i.e. from PMGP) 8 (22.2) 
Email/Internet 8 (22.2) 
* Responses add up to more than I 00% because respondents were allowed to select more than one answer. 
PMGP = Provincial Medical Genetics Program 
4.4 Respondent Attitudes about Current CRC Screening Services in NL 
Table 9 outlines respondent attitudes about current CRC screening services in the 
province. This question involves a repeated five- point Likert scale where one = strongly 
disagree and five = strongly agree. Given that data from the Likert scale is normally 
distributed, mean and standard deviations are used. Almost all respondents either agree or 
strongly agree there is a need for a province wide CRC registry in NL. Many respondents 
feel that family physicians need more continuing education regarding family history of 
so 
CRC and screening. Respondents did not agree that other health professionals besides 
gastroenterologists and general surgeons should be trained to perform colonoscopies. 
Table 9 
s · r . d b >Pecza zst attztu e a out current CRC . NL screenzng servzces zn 
Attitude 
There is a need for a province wide colo rectal cancer registry 
There is a need for a province wide colorectal cancer screening 
central booking centre 
Gastroenterologists need more continuing education around family 
history and CRC screening 
General surgeons need more continuing education around family 
history of CRC screening 
Family physicians need more continuing education around family 
history of CRC screening 
High risk patients (i.e. F AP, HNPCC) should be seeing the same 
gastroenterologist/ general surgeon for follow-up colonoscopies 
Other health professionals besides gastroenterologists/ general 
surgeons should be trained to do colonoscopies 
Wait times for your colonoscopy service is reasonable 
Genetic testing is useful to prioritizing patient care 
You are referring more patients for genetic testing than 5 years 
ago 
There is sufficient support given to those patients who undergo 
genetic testing 
mean (std 
deviation) 
4.36 (0.72) 
3.25 (1.23) 
3.03 (0.87) 
3.34 (0.97) 
4.00 (0.80) 
3.75(1.13) 
2.36 (1.13) 
2.81 (1.28) 
3.25 (1.00) 
3.12 (1.01) 
3.51 (0.70) 
CRC = colorectal cancer; AP = adenomatous polyps; F AP = familial adenomatous polyposis; HNPCC = 
hereditary non-polyposis colorectal cancer 
At the end of the survey, respondents are given the opportunity to provide 
additional comments. Some of the comments included: 
• "I was going to get the screening guidelines from the CAG [Canadian 
Association of Gastroenterology] online but since I am not a member I would have 
had to pay for getting their guidelines ". 
• "Approving province wide system may not work as well or as effective as a 
regional program with dedicated staff who therefore knows the patients personally. 
51 
• "I'm not aware "genetic testing" is routinely being available in this province? 
HNPCC screening begins 5 yrs younger than affected family member". 
• "!found little practical help from genetic referral and their recommendations 
were essentially identical in regards to stratification. 
• "I have little or no contact with the PMGP. As a result I tend to leave it to the 
family doctor to refer. This is less than ideal and I would like to have more info on 
genetics service re: screening in breast as well as CRC". 
• "Does a proposed central booking registry have to be located in Avalon??? I 
suspect it is pre ordained". 
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Chapter Five - Discussi(Jn 
This study examined the characteristics, knowledge, practice patterns and attitudes 
of gastroenterologists and general surgeons in NL regarding CRC screening. CRC 
screening is relevant to both of these groups as they provide the majority of specialized 
diagnostic testing and surgical therapy for CRC. They are the only providers of 
colonoscopy in NL, the preferred test for screening many of the high risk familial and 
hereditary CRC populations (Alberta Cancer Board, 2008; Leddin et al. , 2004; Levin et 
al., 2008). These specialists play a pivotal role in ensuring that residents ofNL receive 
recommended preventive health care. They also act as opinion leaders to their colleagues 
in family practice (Hilsden et al. , 2004b ). 
The response rate of 84% is considered high, particularly among physician 
surveys (Kellerman & Herold, 2001). Even the National Physician Survey which is 
Canada's most comprehensive and authoritative survey of physicians, medical students, 
and residents only received a response rate of35.9% in 2004 (Grava-Gubins & Scott, 
2008). However, given the relatively small number of specialists eligible to participate, it 
was imperative that the majority would respond in order to adequately address the 
research objectives. Such a high response rate even on its own, speaks to the interest the 
specialists have on the topic. 
5.1. Characteristics of the Sample 
Respondents are representative of all specialists performing colonoscopies in NL 
with the exception of community size of practice. One-quarter of the respondents are 
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gastroenterologists and this includes all gastroenterologists currently practicing in the 
province (n = 9). Only one of these gastroenterologists indicated he or she practices in a 
rural setting ( <1 0,000), meaning the majority of the higher risk CRC population (i.e. 
HNPCC and F AP mutation carriers) who often reside in small rural outport communities 
(Woods, Hyde, Curtis, Stuckless, Green, Pollett, et al., 2005) are seeing general surgeons 
for colonoscopy or are traveling to a larger centre to see a gastroenterologist. While it is 
likely these general surgeons obtain professional certification around colonoscopy and 
screening high risk CRC patients (i.e., only 11.4% indicated they were non-certified 
specialists), they may have received less specialized training compared to 
gastroenterologists (Hilsden et al. , 2007). 
5.2 Knowledge and Practice Patterns 
Overall it appears the majority of specialists are aware of the recommended ages 
to begin CRC screening for the different groups of patients. As compared to the 35 
gastroenterologists surveyed by Schroy and colleagues (2002), slightly fewer respondents 
from this study know to begin screening patients with a family history of CRC at 40 years 
of age or ten years earlier than the youngest diagnosed family member (91% vs. 85% ). In 
contrast, significantly more respondents from this study (69%) are aware to begin 
screening patients with a family history of AP at 40 years of age or ten years younger 
than the earliest diagnosed family member as compared to 3 7% of participants in the 
Schroy et al. (2002) study. This may be attributed to the increased awareness among 
specialists of the CRC risk associated with these polyps. 
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A large number of specialists prefer colonoscopy for screening all groups of 
patients despite evidence to support the effectiveness of other tests. This increased 
preference for colonoscopy has been attributed to media coverage (Cram, Fendrick, 
lnadomi, Cowen, Carpenter & Vijan, 2003) documenting the advantages of colonoscopy, 
as well organizations adopting them into their guidelines as the gold standard (Alberta 
Cancer Board, 2008; Leddin et al., 2004; Levin et al. , 2008). Despite guidelines that 
specify FS for screening patients with FAP, only 23% of respondents selected this test for 
screening this group of patients. However, this is likely due to the polyp locations in F AP 
families in NL. NL F AP families are not typical of most F AP gene mutation carriers 
because polyps may occur only in the right colon, making colonoscopy the preferred 
screening test (Dr. J. Green, Medical Geneticist at Memorial University, personal 
communication, May 9, 2009). 
In terms of time demands on the specialist, there does not appear to be much 
difference between FS and colonoscopy. The average FS takes 5-10 minutes while the 
average colonoscopy takes 5-20 minutes (although it can take up to 60 minutes) (Dr. W. 
Pollett, Chair of Surgery with the Faculty of Medicine at Memorial University, personal 
communication, July 7, 2009). Remuneration increases based on the distance the scope 
travels (Medical Care Plan, 2009), however, this increase is not overly significant and a 
specialists' choice of procedure is more dependent on medical indication (Dr. W. Pollett, 
Chair of Surgery with the Faculty of Medicine at Memorial University, personal 
communication, July 7, 2009). Therefore, it does not appear that preference for 
colonoscopy would be due to higher remuneration. 
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Given the increased preference for colonoscopy, improvement around quality 
indicators for this procedure is needed (Hilsden et a!. , 2007). As previously discussed, 
100 colonoscopies or gastroscopies annually was found to be associated with a significant 
improvement in the rate of completion (Wexner, Garbus & Singh, 2001 ). There are two 
specialists who report performing less than this amount. Even though this is a small 
percentage, a negative experience with colonoscopy potentially deters a patient from 
future adherence to screening. For example, an HNPCC mutation carrier living in NL 
confided about a horrendous experience with colonoscopy. In this case, the colonoscopy 
was not performed by the usual specialist and the individual openly stated he/she would 
never go through it again. Another individual was extremely traumatized by the 
colonoscopy experience and speculated that not enough medication was given and would 
rather die before getting it done again (J. Stokes, Research Coordinator, personal 
communication, October 21 , 2008). 
5.2.1. Interdisciplinary Health Team Involvement 
Despite extended wait times for colonoscopy for the general (average risk) 
population there are low levels of support among the specialists for allowing other health 
professionals to provide this service. However, this support might be different for the 
provision of other recommended CRC screening tests. Ontario, for example, is exploring 
the use of a nurse FS program which would be located at a colonoscopy hub in their new 
provincial CRC population-based screening program. According to Linda Rabeneck, 
Regional Vice President of Cancer Care Ontario and former Director of the Division of 
Gastroenterology at the University of Toronto: 
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If I 0% or even I5% of persons who have a FS have an abnormal examination and 
go on to require colonoscopy, this is fewer than the I 00% that would have a 
colonoscopy if we were to use colonoscopy as the initial screening test in average-
risk individuals (Rabeneck & Adams, 2006, p. 249). 
It is not possible to determine from the findings whether colonoscopies done by 
specialists are for CRC screening or for other reasons (e.g., for other illnesses or for the 
management of CRC patients versus screening for CRC). Using colonoscopy to screen 
the general (average-risk) population is thought to place individuals unnecessarily at risk 
for severe consequences from colonoscopy (e.g., bowel perforation, hemorrhage and 
death), while inadvertently increasing health care costs (Sewitch et al., 2006). Further 
study is needed to understand how colonoscopy is being used in NL and to assess whether 
other modalities (e.g., FS) for CRC screening may be more appropriate for some general 
(average risk) patients. This type of information will help assess how best to 
accommodate the rising demand for colonoscopy. 
As discussed earlier, genetic confirmation is shown to enhance adherence to 
screening recommendations and genetic counselors help to ensure the appropriate 
information is relayed to patients (Wagner et al. , 2005; Halbert et al. , 2004; Hadley et al. , 
2004). While almost all specialists include the PMGP for patients with FAP, fewer are 
doing so for HNPCC patients. Similarly, fewer specialists refer suspected HNPCC 
patients for genetic testing as compared to suspected F AP patients. One reason for this 
difference has been attributed to possible gene mutations associated with HNPCC that 
have not yet been identified (Dr. J. Green, Medical Geneticist at Memorial University, 
personal communication, June I3, 2009). This would make it difficult for specialists to 
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differentiate patients with a strong family history of CRC from those who potentially 
carry a gene mutation associated with HNPCC. In any case, genetic testing in NL is only 
available through the PMGP so all specialists recommending genetic testing would need 
to go through this program (Dr. J. Green, Medical Geneticist at Memorial University, 
personal communication, June 13, 2009). Findings highlight the need for increased 
continuing medical education among specialists about the genetic testing process in the 
province. Further study around referral patterns between specialists and the PMGP would 
highlight means of improving communication and coordination between the two. 
There is little consensus or clarity around the roles of the patient and different 
health professionals in the on-going monitoring of high risk familial and hereditary CRC 
patients. Eighty percent of specialists indicate they take the time to collect family 
histories of CRC and AP from their patients as well as discuss the advantages and 
disadvantages associated with the different screening tests. However, time restraints 
likely make it impossible for the specialists to fully address patients' questions, concerns 
and emotional needs in regards to living with a familial or hereditary risk for CRC. For 
HNPCC mutation carriers, adjusting to a life of screening has been described as being 
emotionally draining (J. Stokes, Research Coordinator, personal communication, October 
21 , 2008). Continued collaboration among health professionals (e.g. family physicians, 
specialists, PMGP, etc.) would help to clarify the roles of the different specialists and also 
ensure patients receive the support they need. It is interesting that more than 60% of the 
specialists feel that family physicians should be involved in monitoring high risk CRC 
patients' compliance to screening yet almost all either agree or strongly agree that family 
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physicians need more continuing education about family history and CRC screening 
guidelines. 
Survey findings indicate specialists prioritize high risk CRC patients and that 
more than half of them are seeing HNPCC and F AP mutation carriers within 3 months of 
referral. More strikingly, a large proportion of the general (average risk) population wait 
in excess of one year for colonoscopy. While the Canadian Association of 
Gastroenterology has set benchmarks that recommend a colonoscopy be completed within 
two weeks for patients referred because of high likelihood of cancer based on imaging or 
physical exam (Paterson et al., 2006), guidelines are not available to assess the 
appropriateness of wait times for other groups of patients. Further monitoring of this 
process would help to understand if the use of other health professionals or other 
screening tests might decrease screening wait times. 
5.3 Attitudes 
An overwhelming number of specialists strongly agree there is a need for a 
province wide CRC registry. This is also the position of the Screening Working Group of 
the Provincial Cancer Control Strategy (CCS, 2006) in NL. Similar to the National 
Bowel Cancer Screening Program in the UK, a registry would allow for a more 
comprehensive understanding of the geographic distribution of CRC incidence in the 
province including those families at highest risk for the disease. A registry could be 
customized to allow for the monitoring of patient compliance to screening protocols while 
ensuring different health professionals are aware of a patient's health status regardless of 
direct involvement during a particular visit to the hospital. 
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In the event NL moves towards a provincial CRC screening program, close 
examination of the existing Breast Cancer Screening Program currently operating in the 
province would be helpful. All women aged 50-69 are recruited into this program and 
they do not require a physician referral. The program tracks all women referred for 
follow-up, to the point of diagnosis. All the cases that are referred for further follow-up 
are reviewed once the follow-up is completed. This is done for quality assurance 
purposes. Women that are due for repeat screen are contacted and reminded to book an 
appointment for repeat screening. Since the program began in 1996 through to 2006, 
29,500 women had been screened and 549 cancers detected (CCS, 2006). 
5.4 Study Strengths 
Use of self-administered mail-out surveys was the preferred type of data 
collection instrument for this study because this is relatively inexpensive, not labor 
intensive, has a rapid turnaround in data collection and are the most practical for reaching 
the widely geographically distributed gastroenterologists and general surgeons across the 
province (Dillman, 2007). Because all gastroenterologists and general surgeons in the 
province were invited to participate in the study there was minimal risk of selection bias 
which can result from systematic differences in characteristics between those who are 
selected for a study and those who are not (Polit & Beck, 2004). 
Given the relatively low numbers of gastroenterologists and general surgeons 
performing colonoscopies in the province, a high response rate was paramount to the 
success of the study. This is also important to avoid sampling error which occurs when 
the precision of sample estimates is limited by the number of persons surveyed (Dillman, 
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2007). For this reason, the Tailored Design Approach for Mail and Internet Survey 
(Dillman, 2007) combined with input from "opinion leaders" was used to enhance the 
response rate. An "opinion leader" is defined by Kitson, Harvey, & McCormack (1998) 
as "an individual who is able to influence other individual's attitudes or overt behavior 
informally in a desired way with relative frequency" (p.152). This is shown to be 
particularly useful among clinicians (Lomas, 1997). 
This study not only achieved a high response rate but there were very few missing 
values for the entire data set or for any individual question. It is the first study conducted 
in the province to examine the knowledge, attitude and practice patterns of endoscopy 
specialists involved with screening high risk familial and hereditary CRC populations. It 
is also among very few studies conducted in Canada on this topic. Exploring similar 
studies in the US, such as the Schroy et al. (2002) study allowed for certain survey 
questions to be adopted which added to the methodological rigor of the study. 
Meanwhile, consulting a Medical Geneticist involved with the PMGP, a Medical Ethicist 
and a Health Policy Professor from Memorial University in the development and 
interpretation of the study findings helped to ensure study conclusions and 
recommendations provide the necessary evidence and steps needed for planning for an 
improved CRC screening service in NL. 
5.5 Study Limitations 
The self-administered mail-out survey relied on respondents' ability to recall 
information and/or activities done in the past. Therefore inaccurate recall and bias are 
limitations to this method, particularly among respondents who perform colonoscopies 
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less frequently in their practice (Dillman, 2007). Social desirability is also a potential 
limitation as respondents may give answers that are congruent with prevailing social 
values (Polit & Beck, 2004). While questions in this survey are not intended to impose 
any risk of a socially unacceptable characteristic or behavior, and confidentiality and 
anonymity of responses is guaranteed, some respondents may have felt pressured to 
answer questions based on socially accepted standards and/or published clinical practice 
guidelines rather than personal practice. According to Dillman (2007), people are more 
likely to give honest answers to self-administered surveys than to interview questions; 
however, there is still a risk with this method (Klesges, Baranowski, Beech, Cullen, 
Murray, et al., 2004). Respondent knowledge of the relatively small sample included in 
the study may also contribute to specialists giving socially desirable responses. 
Although the sample includes a slightly higher proportion of specialists working 
in rural regions ofNL, there has been an increase in Medical Geneticist visits to rural 
areas to inform them about familial and hereditary CRC (Dr. J. Green, Medical Geneticist 
at Memorial University, personal communication, July 13, 2009). Therefore, findings are 
not speculated to underestimate specialist knowledge on this topic despite challenges that 
rural physicians often face in receiving continuing medical education. However, it is 
possible that the level of satisfaction towards a centralized CRC screening booking centre 
is overestimated. Rural specialists are more exposed to the challenges and frustrations 
patients face when navigating through an unfamiliar health care system alone and seeking 
screening on an ad hoc basis (Dr. J. Green, Medical Geneticist at Memorial University, 
personal communication, July 13, 2009). A centralized booking centre would likely be 
viewed as an opportunity for more equal and efficient access to care. 
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Chapter Six- Conclusion 
6.1 Summary of Findings 
Gaining a better understanding of the knowledge, practice patterns and attitudes of 
gastroenterologists and general surgeons, the primary providers of colonoscopies in NL, 
is a key initial step in planning for an improved CRC screening service for the province. 
Through a cross-sectional, descriptive survey, this study demonstrates that the majority of 
gastroenterologists and general surgeons in NL are knowledgeable about screening 
guidelines and the appropriate age to begin screening. However, despite best practice 
guidelines, most specialists prefer to screen using colonoscopy rather than other 
recommended screening tests. 
Survey findings suggest that gastroenterologists and general surgeons do not 
generally consider themselves to be responsible for monitoring screening compliance of 
the high risk familial and hereditary CRC patients. Yet, there was no clear consensus 
from the findings who they do consider responsible. There was also inconsistent 
involvement of other health professionals in the screening process. Experiences from 
existing CRC screening programs tell us that close monitoring of a patient' s screening 
compliance and the involvement of other health professionals leads to better health 
promotion, health education, satisfaction among patients, more consistent messaging, 
improved timeliness and quality of care. 
While most specialists indicate they prioritize high risk patients, they also report 
that the general (average risk) population may have long waits to access routine 
colonoscopy screening. Further research is needed to assess the appropriateness of these 
63 
wait times as well as the use of other screening tests in order to improve the management 
of colonoscopy services in the province. Findings also suggest there is strong support for 
a CRC registry, which would be a key component of an organized CRC screening 
program. Based on the findings we recommend: 
1) Examining wait times and indications for colonoscopy in NL. This 
information will help to inform better management as we face a 
growing demand for colonoscopies. 
2) Implementing collaborative model for CRC care and drawing on 
existing CRC screening programs for guidance. 
3) Continuing medical education for gastroenterologists and general 
surgeons, particularly around the types of services offered through the 
PMGP. 
4) Future research on the knowledge, practice patterns and attitudes of 
other health professionals involved with CRC screening. Gathering 
similar information from other health professionals may indicate unique 
strategies for improving CRC screening services in the province. 
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Appendix A - Clinical Criteria for HNPCC 
Table 5. Clinical Criteria for HNPCC 
Amsterdam Criteria07 (for Clinical Identification of HNPCC) 
At least 3 relatives with colonectal cancer plus all of the following: 
One affected patient Is a first-degree relative of the other two 
Two or more successive generations affected 
One or more affected relative received coloreotal cancer diegnosis at ege < 50 years 
FAP excluded 
Tumors verified by pathologic examination 
Amsterdam I~ (Criteria for Clinical Identification of HNPCC, modified to take into account the increased occurrence of cancer other then of 
the colon and rectum) 
At least 3 relatives with an HNPCC-e11soclated cancer (colorectal onncer and cancer of the endometrium, small bowel, ureter, or renal 
peiYls}' plus all of the following: 
One affected patient Is a first-degree relative of the other two 
Two or more sucre11slve generations affected 
One or more affected relative received colorectal cancer dlegnosls at ege < 00 years 
FAP excluded In any ease of colo"'ctal cance,. 
Tumors verified by pathologic examination 
Bethesda Guldellnesca (For Identification of patients with colorectal tumors who should undergo testing for mlcrosatelllte instability) 
B1 - Individuals with cancer In families that meet the Amsterdam Criteria 
B2 - Individuals with 2 HNPCC-related tumors, Including synchronous and metachronous colorectal cancer or associated extracolonic 
cancer (endometrium, ovarian. gastric, hepatoblllary, or small-bov.el cancer or transitlona~cell carcinoma of the renal pelvis or ureter) 
83 - Individuals wi.th oolorectal cancer and a first-degree relative with colo rectal cancer or HNPCC-felated extraoolonio cancer or a 
ooloreotal adenoma; one of the cancers diagnosed at age < 4!5 ~ars,' and the adenoma diagnosed < 40 years 
B4 -Individuals with colorectal cancer or endometrial cancer diagnosed at age < 4!5 years!' 
65 - Individuals with right"Sided colorectal cancer with an undifferentiated pattem (solid, cribriform) on histopathology diagnosed at ega 
< 45 years!' (solid or cribrifonm). defined as poorly differentiated for undifferentlated carcinoma composed of irregular, solid sheets of 
large eosinophilic cells and containing small glancHike spaces 
66 - Individuals with slgnet·rlng-rell t)lJe colorectal cancer diagnosed at age < 45 yearsb (composed of > 50% signet-ring cells) 
B7 - individuals with adenomas diagnosed at age < 40 years 
•Differences betv.een Amsterdam end Amsterdam II In bold. 
bModified Bethesda criteria replace the age of · < 45" for colorectal cancer diagnosis in 83, B4, B5, and 86 to ·<~·; see reference 73• 
Adapted and reprinted with permisslon .~02 
Note. From Winawer, Fletcher, Rex, Bond, Burt, Ferrucci, et al., 2003 . Used with 
permission of the author. 
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Appendix B -Performance Characteristics of CRC Screening Tests 
I Screening Metllod i Advantages I Disadvantages Sensitivity Specificity 
I FOBT • EAs-y safe, mexpe:tlstve, • Requires patient action 35 -50% for 98-99% 
convenient and simple to for completion of test ( cancer (one-time 
complete stool collection) FOBT) 
• Strong evidence from • Patients may find test 
randomiz.ed controlled unpleAsant to do 
ttials of reduction • No direct visualization of 
I i in c<>lorectal cancer 
the colorechun 
I morU!lity with screening • May miss many polyps 
! I 
Flexible I • Usually weU tolernted • Requires. bowel 50-70% of I 
Sigmoidost>opy I without sedation I preparation advanced 1• Moderate cost • PAtients may find adenomas and 
• Good evidence of test uncomfortable or cancer 
reduction in modality emban11ssing 
I with screenin!Z • Small risk of perforation 
I - 1 or bleeding I • Screens only about half 
I the colon. I 
1 Double Coutmst ! • Screens full colorectum • Requires bowel 48% for large 85% tor cancer I Baa·ium Enema • Sedation is not l'Cquired preparation adenomas 
• Relatively safe • Exposure to rndiation (> lcm) I• Patients may find 
I 1 test uncomfortable or 55-85% for 
i embarrassing cancer ! • No controlled t1ials 
I 
I 
evaluate its effectiveness I 
! for CRC screening 
' I • Direct visualization of I Colouoscopy • Requires bowel 90% for polyps 99%. 
j the entire colorechun I preparation > lcm 
I • Allows for removal of ! • Patients need to be 
I 
1 
polyps at the same time escorted home and are > 90% for cancer I 
I • Reduction in CRC advised not to go back to 
! mmtality iu FOBT work the same day 
I trials is athibutable to i • Small risk of bleeding ! and perforation 
i follow-up diagnostic I • Patients may find 
colonoscopy I test uncomfortable or 
I I emban'Bssing 
Note. From the Alberta Cancer Board (2008). Used with permission of the organization. 
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Appendix C- CAG Algorithm to Screening (a) average risk population 
and (b) high risk population 
(a) 
Negative Family 
History 
I No Rercening 
figure 1) Approach to a mag~ risk sal't'niTJt 
Symptomatic 
Negative Family 
History 
Diagnostic Work-up 
A vcrage Risk screening: 
Screening tool to be 
determined by 
pbysicirut, plll'ient 
preference, evidence and 
available resources. 
Note. From Leddin et al. , 2004. Used with permission of the author. 
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l 
HNPCC 
orFAP 
O<mctic 
Counseling & 
Special 
Screening 
IiNl>CC: 
Colono ·c<tpy every 
l-2 years. 
Begin al age 20 
years or 10 ye~us 
younger than the 
earlic t case in the 
tiunily, whichever 
com •s first. 
FAP: 
Sigm.oidoscopy 
amnmlly, Begin at 
age I 0-12 years 
JlC 
Colonoscopy 
anmutlly. 
Begin 11t age Hi-18 
years 
(b) 
I Men and Women Symptomatic 
l 
Asymptomatic 
Regardle · of age 
But 
Positive Fmnily History 
Ond first-ddgrcc 
relati e with 
cru1cer or 
adenomatotL<; 
polyp at age 
0 
or 
Two or more 
ftrSt-degree 
rclativet~ with 
polyp or colon 
cancer at any 
age 
Colonosc:opy 
t>\l'et'Y 5 yoot •• 
B~gin at age 
40or 
10 years earlier 
than the 
youngest 
di.agnosis of 
pol p or CtlllCCf 
jo tbe fatni ly, 
whichever 
comes first 
One first-
degree relative 
with cancer or 
adenomatotll 
polyp affected 
at age > 60 
or 
Two or more 
second-degree 
relatives with 
polyps or 
cancer 
Avel"age-
rhk 
s<::rt>oening. 
Begin at age 
40 
Diagno.siie rk-up I 
One . e-cond-
degree relative 
or 
third-degree 
relntive 
affected 
' 
Average-
risk 
c:ree:nlng. 
Begin at age 
50 
Polyps found 
at colonoscopy 
1-2. tubular 
adenomas < 1 
em: 
Colonoscopy in 
5 i)lll'ti. 
> 2 aden.<>mas: 
Colonoscopy in 
3 years 
Incomplete 
examination, 
numerous 
pol ps, advtm~'\Cd 
adenomn, 
malignnnt or 
lnrge se . ile 
.ad noma; 
Colono.s op 
after a short 
interval bt\sed n 
clinical judgrm."fft 
Note. From Leddin et al., 2004. Used with permission of the author. 
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Appendix D - Cover Letter and Survey 
UNIVERSITY 
COLORECTAL CANCER SCREENING SURVEY FOR 
GASTROENTEROLOGISTS AND SURGEONS 
February 2009 
Dear Physician, 
Newfoundland and Labrador has the highest rate of co lor ectal cancer of any Canadian province. 
We're interested in finding out about your knowledge, attitude and practice patterns regarding 
patients who have personal or family history of colorectal cancer or adenomatous polyps. The 
attached survey should take less than 10 minutes to complete. The results will be useful in planning 
for an improved colorectal cancer screening service in the province. 
Please return the completed survey in the envelope provided along with the postcard which is to be 
mailed separately. Only the postcard will have your identification information to ensure anonymity 
of responses while providing us with a list of physicians who have completed and returned the 
survey. 
I am a M.Sc. student in the Faculty of Medicine doing this research for my thesis and I work under 
the supervision of Dr. Jane Green, Medical Geneticist also in the Faculty ofMedicine. I fyou have 
any questions or would like go through the survey together over the telephone my contact 
information is below. Thank you for your cooperation. 
Sincerely, 
Jill MacEachern 
Graduate Student 
Atlantic Regional Training Centre 
Faculty ofMedicine 
Memorial University ofNewfoundland and Labrador 
St. John's, NL, AI B 3V6 
Phone: 709-749-6130 
Email: jill.maceachern@mun.ca 
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SECTION 1- Physician Personal and Practice Characteristics 
Please answer each of the following questions by placing a check (V} in the appropriate box 
1. What is your specialty? D Gastroenterology D Surgery 
D Other (specify): ________ _ 
2. What is your gender? D Female D Male 
3. How many years ago did you graduate? 
D < 10 years ago D I 0-20 years ago D 20-30 years ago D 30+ years ago 
4. How long have you practiced in Newfoundland and Labrador? ___ year(s) 
5. By what professional body are you certified? 
D Royal College of Physicians and Surgeons of Canada 
D American Board of Surgery 
D American Board of Internal Medicine 
D Non-Certified Specialist 
D Other (specify) : _________ _ 
6. How large is the community in which you practice? 
7. Do you perform colonoscopies in your service? 
D rural (<10,000) 
D small urban (10,000-100,000) 
D urban (> I 00,000) 
D Yes 
D No-If NO, please stop here and go to 
Question 20 
8. Approximately how many years have you been performing colonoscopies? year(s) 
9. Approximately how many colonoscopies do you perform every year? I year 
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SECTION II- Hereditary Colorectal Cancer Screening 
10. What percent of your asymptomatic patients age Jess than 40 do you ask about a fu.mily history of 
colorectal cancer or polyps? 
D o-25% 
D 26-50% 
D 5t-75% 
D 76-too% 
I I. What percent of your asymptomatic patients age 40 and above do you ask about a family history of 
colorectal cancer or polyps? 
D o-25% 
D 26-50% 
D 5t-75% 
D 76-too% 
12. For the following groups, please identifY the age you would recommend to begin screening, the 
screening modality, other health professionals you would involve and if you routinely recommend 
test' 
Family History of Colorectal Cancer 
(single first-degree relative with colorectal cancer diagnosed at younger than age 55) 
Age you recommend to begin screening: D 15-24 years D 25-39 years D 40-49 years D 50+ years 
Screening modality most frequently used: 
D Digital rectal exam D Fecal occult blood test (FOBT) 
D Flexible sigmoidoscopy D Combination ofFOBT and sigmoidoscopy 
D Colonoscopy 
D Do not screen 
Other health professionals you involve: 
D Other Gastroenterologists/ Surgeons 
D Family Doctor 
D None 
D Double-contrast barium enema 
D Other (please specify): 
-------
D Provincial Medical Genetics Program /Genetic Counsellor 
D Gynaecologist/ Urologist 
D Other (specify):. ______ _ 
Would you routinely recommend genetic testing? D Yes D No 
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Family History of Adenomatous Polyps 
(single fLrst-degree relative with adenomatous polyp diagnosed at younger than age 60) 
Age you recommend to begin screening: D 15-24 years D 25-39 years D 40-49 years D 50+ years 
Screening modality most frequently used: 
D Digital rectal exam D Fecal occult blood test (FOBT) 
D Flexible sigmoidoscopy D Combination ofFOBT and sigmoidoscopy 
D Colonoscopy 
D Do not screen 
Other health professionals you involve: 
D Other Gastroenterologists/ Surgeons 
D Family Doctor 
D None 
D Double-contrast barium enema 
D Other (please specify): 
-------
D Provincial Medical Genetics Program /Genetic Counsellor 
D Gynaecologist/ Urologist 
D Other (specify):. ______ _ 
Would you routinely recommend genetic testing? D Yes D No 
Familial Adenomatous Polyposis (FAP) 
Age you recommend to begin screening: D 15-24 years D 25-39 years D 40-49 years D 50+ years 
Screening modality most frequently used: 
D Digital rectal exam D Fecal occult blood test (FOBT) 
D Flexible sigmoidoscopy 
D Colonoscopy 
D Do not screen 
Other health professionals you involve: 
D Other Gastroenterologists/ Surgeons 
D Family Doctor 
D None 
D Combination ofFOBT and sigmoidoscopy 
D Double-contrast barium enema 
D Other (please specify): 
-------
D Provincial Medical Genetics Program /Genetic Counsellor 
D Gynaecologist/ Urologist 
D Other (specify): ______ _ 
Would you routinely recommend genetic testing? D Yes D No 
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Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
previously known as Lynch Syndrome 
Age you recommend to begin screening: 0 15-24 years 0 25-39 years 0 40-49 years 0 50+ years 
Screening modality most frequently used: 
0 Digital rectal exam 0 Fecal occult blood test (FOBT) 
0 Flexible sigmoidoscopy 0 Combination ofFOBT and sigmoidoscopy 
0 Colonoscopy 
0 Do not screen 
Other health professionals you involve: 
0 0ther Gastroenterologists/ Surgeons 
0 Family Doctor 
0 None 
0 Double-contrast barium enema 
0 Other (please specify): 
--------
0 Provincial Medical Genetics Program /Genetic Counsellor 
0 Gynaecologist/ Urologist 
0 Other (specify): ______ _ 
Would you routinely recommend genetic testing? 0 Yes 0 No 
13. What method of colorectal cancer screening do you recommend for your asymptomatic patients who 
are age 50 and older with no significant family of history of colorectal cancer or polyps? 
0 Digital rectal exam 
0 Fecal occult blood test (FOBT) annually 
0 Flexible sigmoidoscopy every 5 years 
0 Combination ofFOBT and flexible sigmoidoscopy every 5 years 
D Colonoscopy every 10 years 
0 Double-contrast barium enema every 5-10 years 
0 Do not screen 
0 Other (please specify): ______ _ 
14. Do you discuss advantages/disadvantages associated with different screening approaches with your 
patients? 0 Yes 
0 No 
If YES, do you give patients the opportunity to apply their own preference in selecting how they are 
screened? 0 Yes 0 No 
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15. In the table below, please indicate when the next colonoscopy appointment would be available for the 
different groups by placing a check(../) under the appropriate time frame. 
< month 1-3 months 3-6 months 6-12 > 12 Not 
months months Applicable 
Family history of D D D D D 
colorectal cancer 
Family history of D D D D D 
adenomatous polyps 
FAP and HNPCC D D D D D 
General population D D D D D (> 50 years old) 
16. Do you have a systematic approach to prioritizing patients for your colonoscopy service? 
D Yes D No 
If YES, on what basis do you prioritize? 
17. Who should be responsible for monitoring hereditary colorectal cancer patients' compliance to 
screening? 
D The patient 
D Yourself 
D Provincial Medical Genetics Program/ Genetic Counsellor 
D Family Doctor 
D Other (specify): ________ _ 
D 
D 
D 
D 
18. Where have you read or heard information pertaining to risk factors and screening recommendations 
for hereditary colorectal cancer (check all that apply ) 
D Medical Journals D Hospital Rounds 
D Colleagues D Patient letter from the Provincial Medical Genetics Clinic 
D Patients D Other (specify): _____ _ 
What is your preferred method of receiving this information? ___________ _ 
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SECTION Ill: Attitude about Current Colorectal Cancer Screening Services 
19. On a scale of I to 5 how strongly do you agree with each statement? (circle one for each statement) 
Strongly Disagree Neither Agree Strongly 
Disagree Agree or Agree 
Disagree 
a. There is a need for a province wide I 2 3 4 5 
colorectal cancer registry 
b. There is a need for a province wide I 2 3 4 5 
colorectal cancer screening central booking 
centre which would include my colonoscopy 
service 
c. Gastroenterologists could use more I 2 3 4 5 
continuing education around family history 
and colorectal cancer screening 
d. Surgeons could use more continuing I 2 3 4 5 
education around family history and 
colorectal cancer screening 
e. Family physicians could use more I 2 3 4 5 
continuing education around family history 
and colorectal cancer screening 
f. High risk patients (i.e. HNPCC and F AP) I 2 3 4 5 
should see the same gastroenterologist or 
surgeon for follow-up colonoscopies 
g. Other health professionals besides I 2 3 4 5 
gastroenterologists and surgeons should be 
trained to perform colonoscopies 
h. Wait times for my colonoscopy service is I 2 3 4 5 
reasonable 
i. Genetic testing is useful to me for I 2 3 4 5 
prioritizing patient care 
j. I am referring more patients for genetic I 2 3 4 5 
testing than 5 years ago 
k. There is sufficient support given to those I 2 3 4 5 
patients who undergo genetic testing 
20. Do you have any additional comments? 
You have now completed the survey. Please return it in the envelope provided. 
Thank you 
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Appendix E - Postcard for Tracking Survey Responses 
From: Business reply 
postage here 
Colorectal Cancer Screening Study 
c/o Daryl Pullman, Room 2832 
Division of Community Health & Humanities 
Health Science Centre 
300 Prince Philip Drive 
St. John's NL 
AlB 3V6 
Please check one of the following: 
D Would you be willing to be contacted for a follow-up 
interview? 
D Please send me a summary report of the study 
D Please do not send me a summary report of the study 
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Appendix F: Survey Variables and Coding Scheme 
Variable Name Q# Category Codes 
Specialty Ql Gastroenterology I 
Surgery 2 
Other 3 
Sex Q2 Female I 
Male 2 
Year of graduation from medical school Q3 less than 10 I 
10-20 2 
20-30 3 
more than 30 4 
Years practicing in NL Q4 less than 10 I 
10-30 2 
more than 30 3 
Professional certification Q5 RCPSC I =yes 
America Board of Surgery 2=no 
America Board of Internal Medicine 
Non-Certified Specialist 
American College of General surgeons 
South African Medical and Dental Ass. 
Community size of practice Q6 <100,000 I 
> 100,000 2 
Colonoscopy performed in practice Q7 Yes I 
No 2 
Years performing colonoscopy Q8 Less than 10 I 
10-30 2 
More than 30 3 
Average annual number of colonoscopies Q9 less than I 00 1 
performed 101-250 2 
25 1-500 3 
501-750 4 
more than 750 5 
Percent of asymptomatic patients <40 yrs QIO 0-25% I 
that are asked about family history ofCRC 26-75% 2 
76-100% 3 
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Percent of asymptomatic patients >40 yrs Qll 0-25% I 
that are asked about family history ofCRC 26-75% 2 
76-100% 3 
Family history CRC; Family history AP; Ql2 Age 
FAP; HNPCC 15-24 years I 
- age begin screening 25-39 years 2 
-screening modality 40-49 years 3 
- other health professionals involved 50+ years 4 
- genetic testing routinely recommended Screening modali!Y l =yes 
DRE 2=no 
FS 
Colonoscopy 
FOBT 
Combo FOBT and FS 
DCBE 
Other health grofessional involvement l =yes 
Other Gls/general surgeons 2=no 
Family doctor 
PMGP/ Genetic counselor 
Gynecologist/Urologist 
Routine recommendation for genetic 
testing 
yes I 
no 2 
Screening of asymptomatic patients >50 QI3 DRE l =yes 
yrs of age FOBT every 1-2 yr 2=no 
FS every 5 yr 
Combo FOBT and FS 
Colonoscopy every I 0 yr 
DCBE 
Do no screen 
Advantages/ disadvantages of different Q14 Yes I 
screening tests discussed with patients. No 2 
Ifyes, influence on type of test used. Yes I 
No 2 
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r---;-------------------------~-------
Wait times for colonoscopy: Q15 < month I 
- Family history CRC 1-3 month 2 
- Family history AP 3-6 month 3 
-FAP 6-12 month 4 
- HNPCC > 12 month 5 
not applicable 6 
Systematic approach to prioritizing care Q16 Yes I 
No 2 
On what basis is care prioritized 
Abnormal lab data occult blood I =yes 
Change in stool pattern 2=no 
Weight loss 
Abnormal barium enema 
Referral from family doctor/nurse 
practitioner 
Referral from PMGP/results genetic 
testing 
Family history 
Personal history of CRC/ polyps 
F AP/HNPCC patients past their 
screening interval 
Age 
Responsibility of monitoring patient Q17 The patient l =yes 
compliance to screening Yourself 2=no 
PMGP/Genetic Counselor 
Family Doctor 
Method of receiving continuing medical Q18 Medical journals 1=yes 
education Patient letter from the PMGP 2=no 
Patients 
Hospital rounds 
Colleagues 
Preferred method of receiving information Textbooks 
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-- -~--~-------~-------------------
Conferences 
CAG 
Internet 
Endoscopy Unit 
No preference l =yes 
Journals 2=no 
Mail 
On-line 
Attitude about existing CRC screening QI9 I 
services: 2 
- CRC registry 3 
- CRC central booking centre 4 
- Gastroenterologists need more cont ed. 5 
- General surgeons need more cont ed. 
- Family physician need more ed. 
- F AP and HNPCC patients should see 
same specialist for follow-up 
- Other health professionals besides 
gastroenterologists/ general surgeons 
should be trained to perform colonoscopies 
- F AP/ HNPCC patients should see same 
specialist for follow- up 
-Wait times for colonoscopy are 
reasonable 
- Genetic testing is useful for prioritizing 
care 
- Referring more patients to genetic testing 
than 5 years ago 
- Sufficient support is given to patients 
undergoing genetic testing 
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Appendix G: Human Investigative Committee Approval Letter 
..... 
..• 
' I • •, 
January 5, 2009 
Reference #08.173 
Ms. Jill MacEachern 
8 Barnes Road 
St. John 's, NL 
AIC 3X2 
Dear Ms. MacEachern: 
This will acknowledge your correspondence dated Jam1ary 5, 2009 wherein you clari t)r issues 
and pro idcd a revised survey for your research study entitled "Colorccta.l Cancer screening: 
Knowledge, attir.udes aud practices of colonoscopy service providers in Newfoundland 
aod Labr.ador". 
This correspondence has been reviewed by the co-chair and Full approval of this research 
study has been granted for one year effecti e January 5, 2009. 
Full approval has been granted for one year. You will be contacted to complete the annual 
form update approximately 8 weeks before the approval will lapse on January 5, 2016. It is 
your responsibility to ensure that the renewal fom1 is forwarded to the HIC office not less than 
30 days prior to the renewal date for review and approval to continue the study. The annual 
renewal forn1 can be downloaded from the HlC website 
l1! tp:i/www. m.:d.mlm.c·. hie/downloads/ Annua 1%20 r-datc%,20F orm.doc. 
For a hospital·based study, it is vour responsibility to seek the necessnrv npprovnl from the 
Health Cure Corporation of St. John's nnd/or other hospital boards as approa)riatc.•. 
This Research Ethics Board (the HlC) has reviewed and approved the application for the study 
which i to be conducted by you as the quali'tied investigator named above at the specified 
study site. This approval and the views ofthis Research Ethics Board have been documented 
in writing. In addition, please be advised that the Human Investigation Committee currently 
operates according to the Tri·Council Policy Statement and applicable laws and regulations. 
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